0000766792 false --12-31 2023 Q2 0000766792 false --12-31 2023 Q2 0 3 10 4 12 15 1 0 0 0 0 00007667922023-01-012023-06-30 thunderdome:item iso4217:USD 0000766792cvv:MesoScribeTechnologiesIncMember2022-12-31 0000766792cvv:MesoScribeTechnologiesIncMember2023-06-30 0000766792cvv:MesoScribeTechnologiesIncMember2023-01-012023-06-30 0000766792cvv:MesoScribeTechnologiesIncMember2023-04-012023-06-30 0000766792cvv:MesoScribeTechnologiesIncMemberus-gaap:SubsequentEventMember2023-08-08 0000766792cvv:TantalineASOfNordborgMember2022-12-31 0000766792cvv:TantalineASOfNordborgMember2023-01-012023-06-30 0000766792cvv:TantalineASOfNordborgMember2023-04-012023-06-30 0000766792cvv:TantalineASOfNordborgMember2023-05-262023-05-26 00007667922022-01-012022-06-30 0000766792us-gaap:CorporateNonSegmentMember2022-01-012022-06-30 0000766792us-gaap:IntersegmentEliminationMember2022-01-012022-06-30 0000766792us-gaap:OperatingSegmentsMembercvv:MaterialsMember2022-01-012022-06-30 0000766792us-gaap:OperatingSegmentsMembercvv:SDCMember2022-01-012022-06-30 0000766792us-gaap:OperatingSegmentsMembercvv:CVDMember2022-01-012022-06-30 0000766792us-gaap:CorporateNonSegmentMember2023-01-012023-06-30 0000766792us-gaap:IntersegmentEliminationMember2023-01-012023-06-30 0000766792us-gaap:OperatingSegmentsMembercvv:MaterialsMember2023-01-012023-06-30 0000766792us-gaap:OperatingSegmentsMembercvv:SDCMember2023-01-012023-06-30 0000766792us-gaap:OperatingSegmentsMembercvv:CVDMember2023-01-012023-06-30 00007667922022-04-012022-06-30 0000766792us-gaap:CorporateNonSegmentMember2022-04-012022-06-30 0000766792us-gaap:IntersegmentEliminationMember2022-04-012022-06-30 0000766792us-gaap:OperatingSegmentsMembercvv:MaterialsMember2022-04-012022-06-30 0000766792us-gaap:OperatingSegmentsMembercvv:SDCMember2022-04-012022-06-30 0000766792us-gaap:OperatingSegmentsMembercvv:CVDMember2022-04-012022-06-30 00007667922022-06-30 0000766792us-gaap:CorporateNonSegmentMember2022-06-30 0000766792us-gaap:IntersegmentEliminationMember2022-06-30 0000766792us-gaap:OperatingSegmentsMembercvv:MaterialsMember2022-06-30 0000766792us-gaap:OperatingSegmentsMembercvv:SDCMember2022-06-30 0000766792us-gaap:OperatingSegmentsMembercvv:CVDMember2022-06-30 00007667922023-04-012023-06-30 0000766792us-gaap:CorporateNonSegmentMember2023-04-012023-06-30 0000766792us-gaap:IntersegmentEliminationMember2023-04-012023-06-30 0000766792us-gaap:OperatingSegmentsMembercvv:MaterialsMember2023-04-012023-06-30 0000766792us-gaap:OperatingSegmentsMembercvv:SDCMember2023-04-012023-06-30 0000766792us-gaap:OperatingSegmentsMembercvv:CVDMember2023-04-012023-06-30 00007667922023-06-30 0000766792us-gaap:CorporateNonSegmentMember2023-06-30 0000766792us-gaap:IntersegmentEliminationMember2023-06-30 0000766792us-gaap:OperatingSegmentsMembercvv:MaterialsMember2023-06-30 0000766792us-gaap:OperatingSegmentsMembercvv:SDCMember2023-06-30 0000766792us-gaap:OperatingSegmentsMembercvv:CVDMember2023-06-30 0000766792us-gaap:IntersegmentEliminationMembercvv:CVDMember2022-01-012022-06-30 0000766792us-gaap:IntersegmentEliminationMembercvv:CVDMember2023-04-012023-06-30 0000766792us-gaap:IntersegmentEliminationMembercvv:CVDMember2023-01-012023-06-30 0000766792us-gaap:IntersegmentEliminationMembercvv:SDCMember2022-01-012022-06-30 0000766792us-gaap:IntersegmentEliminationMembercvv:SDCMember2023-01-012023-06-30 0000766792us-gaap:IntersegmentEliminationMembercvv:SDCMember2022-04-012022-06-30 0000766792us-gaap:IntersegmentEliminationMembercvv:SDCMember2023-04-012023-06-30 xbrli:pure utr:Y 0000766792us-gaap:EmployeeStockOptionMember2023-01-012023-06-30 0000766792us-gaap:EmployeeStockOptionMember2023-06-30 iso4217:USDxbrli:shares xbrli:shares 0000766792cvv:ExercisePriceRange3Member2023-06-30 0000766792cvv:ExercisePriceRange3Member2023-01-012023-06-30 0000766792cvv:ExercisePriceRange2Member2023-06-30 0000766792cvv:ExercisePriceRange2Member2023-01-012023-06-30 0000766792cvv:ExercisePriceRange1Member2023-06-30 0000766792cvv:ExercisePriceRange1Member2023-01-012023-06-30 00007667922023-03-31 00007667922023-01-012023-03-31 00007667922022-12-31 0000766792us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2023-01-012023-06-30 0000766792srt:DirectorMember2023-06-30 0000766792us-gaap:RestrictedStockMembersrt:DirectorMember2022-01-012022-06-30 0000766792us-gaap:RestrictedStockMembersrt:DirectorMember2023-01-012023-06-30 0000766792us-gaap:RestrictedStockMembersrt:DirectorMember2023-04-012023-06-30 0000766792us-gaap:RestrictedStockMembersrt:DirectorMember2022-04-012022-06-30 0000766792us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-06-30 0000766792us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-06-30 0000766792us-gaap:GeneralAndAdministrativeExpenseMember2022-04-012022-06-30 0000766792us-gaap:GeneralAndAdministrativeExpenseMember2023-04-012023-06-30 0000766792cvv:SellingAndShippingMember2022-01-012022-06-30 0000766792cvv:SellingAndShippingMember2023-01-012023-06-30 0000766792cvv:SellingAndShippingMember2022-04-012022-06-30 0000766792cvv:SellingAndShippingMember2023-04-012023-06-30 0000766792us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-06-30 0000766792us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-06-30 0000766792us-gaap:ResearchAndDevelopmentExpenseMember2022-04-012022-06-30 0000766792us-gaap:ResearchAndDevelopmentExpenseMember2023-04-012023-06-30 0000766792cvv:CostOfRevenueMember2022-01-012022-06-30 0000766792cvv:CostOfRevenueMember2023-01-012023-06-30 0000766792cvv:CostOfRevenueMember2022-04-012022-06-30 0000766792cvv:CostOfRevenueMember2023-04-012023-06-30 0000766792cvv:LoanAgreementToFundMachineryAcquisitionMember2022-09-30 0000766792cvv:LoanAgreementToFundMachineryAcquisitionMember2022-09-012022-09-30 00007667922021-12-31 utr:M 00007667922023-07-012023-06-30 0000766792us-gaap:TransferredAtPointInTimeMember2022-01-012022-06-30 0000766792us-gaap:TransferredOverTimeMember2022-01-012022-06-30 0000766792cvv:Research1Member2022-01-012022-06-30 0000766792cvv:Research1Memberus-gaap:TransferredAtPointInTimeMember2022-01-012022-06-30 0000766792cvv:Research1Memberus-gaap:TransferredOverTimeMember2022-01-012022-06-30 0000766792cvv:IndustrialMember2022-01-012022-06-30 0000766792cvv:IndustrialMemberus-gaap:TransferredAtPointInTimeMember2022-01-012022-06-30 0000766792cvv:IndustrialMemberus-gaap:TransferredOverTimeMember2022-01-012022-06-30 0000766792cvv:AerospaceMember2022-01-012022-06-30 0000766792cvv:AerospaceMemberus-gaap:TransferredAtPointInTimeMember2022-01-012022-06-30 0000766792cvv:AerospaceMemberus-gaap:TransferredOverTimeMember2022-01-012022-06-30 0000766792cvv:EnergyStorageAndTransmissionMember2022-01-012022-06-30 0000766792cvv:EnergyStorageAndTransmissionMemberus-gaap:TransferredAtPointInTimeMember2022-01-012022-06-30 0000766792cvv:EnergyStorageAndTransmissionMemberus-gaap:TransferredOverTimeMember2022-01-012022-06-30 0000766792us-gaap:TransferredAtPointInTimeMember2023-01-012023-06-30 0000766792us-gaap:TransferredOverTimeMember2023-01-012023-06-30 0000766792cvv:Research1Member2023-01-012023-06-30 0000766792cvv:Research1Memberus-gaap:TransferredAtPointInTimeMember2023-01-012023-06-30 0000766792cvv:Research1Memberus-gaap:TransferredOverTimeMember2023-01-012023-06-30 0000766792cvv:IndustrialMember2023-01-012023-06-30 0000766792cvv:IndustrialMemberus-gaap:TransferredAtPointInTimeMember2023-01-012023-06-30 0000766792cvv:IndustrialMemberus-gaap:TransferredOverTimeMember2023-01-012023-06-30 0000766792cvv:AerospaceMember2023-01-012023-06-30 0000766792cvv:AerospaceMemberus-gaap:TransferredAtPointInTimeMember2023-01-012023-06-30 0000766792cvv:AerospaceMemberus-gaap:TransferredOverTimeMember2023-01-012023-06-30 0000766792cvv:EnergyStorageAndTransmissionMember2023-01-012023-06-30 0000766792cvv:EnergyStorageAndTransmissionMemberus-gaap:TransferredAtPointInTimeMember2023-01-012023-06-30 0000766792cvv:EnergyStorageAndTransmissionMemberus-gaap:TransferredOverTimeMember2023-01-012023-06-30 0000766792us-gaap:TransferredAtPointInTimeMember2022-04-012022-06-30 0000766792us-gaap:TransferredOverTimeMember2022-04-012022-06-30 0000766792cvv:Research1Member2022-04-012022-06-30 0000766792cvv:Research1Memberus-gaap:TransferredAtPointInTimeMember2022-04-012022-06-30 0000766792cvv:Research1Memberus-gaap:TransferredOverTimeMember2022-04-012022-06-30 0000766792cvv:IndustrialMember2022-04-012022-06-30 0000766792cvv:IndustrialMemberus-gaap:TransferredAtPointInTimeMember2022-04-012022-06-30 0000766792cvv:IndustrialMemberus-gaap:TransferredOverTimeMember2022-04-012022-06-30 0000766792cvv:AerospaceMember2022-04-012022-06-30 0000766792cvv:AerospaceMemberus-gaap:TransferredAtPointInTimeMember2022-04-012022-06-30 0000766792cvv:AerospaceMemberus-gaap:TransferredOverTimeMember2022-04-012022-06-30 0000766792cvv:EnergyStorageAndTransmissionMember2022-04-012022-06-30 0000766792cvv:EnergyStorageAndTransmissionMemberus-gaap:TransferredAtPointInTimeMember2022-04-012022-06-30 0000766792cvv:EnergyStorageAndTransmissionMemberus-gaap:TransferredOverTimeMember2022-04-012022-06-30 0000766792us-gaap:TransferredAtPointInTimeMember2023-04-012023-06-30 0000766792us-gaap:TransferredOverTimeMember2023-04-012023-06-30 0000766792cvv:Research1Member2023-04-012023-06-30 0000766792cvv:Research1Memberus-gaap:TransferredAtPointInTimeMember2023-04-012023-06-30 0000766792cvv:Research1Memberus-gaap:TransferredOverTimeMember2023-04-012023-06-30 0000766792cvv:IndustrialMember2023-04-012023-06-30 0000766792cvv:IndustrialMemberus-gaap:TransferredAtPointInTimeMember2023-04-012023-06-30 0000766792cvv:IndustrialMemberus-gaap:TransferredOverTimeMember2023-04-012023-06-30 0000766792cvv:AerospaceMember2023-04-012023-06-30 0000766792cvv:AerospaceMemberus-gaap:TransferredAtPointInTimeMember2023-04-012023-06-30 0000766792cvv:AerospaceMemberus-gaap:TransferredOverTimeMember2023-04-012023-06-30 0000766792cvv:EnergyStorageAndTransmissionMember2023-04-012023-06-30 0000766792cvv:EnergyStorageAndTransmissionMemberus-gaap:TransferredAtPointInTimeMember2023-04-012023-06-30 0000766792cvv:EnergyStorageAndTransmissionMemberus-gaap:TransferredOverTimeMember2023-04-012023-06-30 0000766792us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMembercvv:CustomerBMember2022-01-012022-06-30 0000766792us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMembercvv:CustomerAMember2022-01-012022-06-30 0000766792us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMembercvv:CustomerBMember2022-04-012022-06-30 0000766792us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMembercvv:CustomerAMember2022-04-012022-06-30 0000766792us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMembercvv:CustomerBMember2023-01-012023-06-30 0000766792us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMembercvv:CustomerAMember2023-01-012023-06-30 0000766792us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMembercvv:CustomerDMember2023-04-012023-06-30 0000766792us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMembercvv:CustomerCMember2023-04-012023-06-30 0000766792us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMembercvv:CustomerBMember2023-04-012023-06-30 0000766792us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMembercvv:CustomerAMember2023-04-012023-06-30 0000766792us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMembercvv:TwoCustomersMember2022-01-012022-12-31 0000766792us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMembercvv:TwoCustomersMember2023-01-012023-06-30 0000766792country:DK2022-12-31 0000766792us-gaap:RetainedEarningsMember2022-06-30 0000766792us-gaap:AdditionalPaidInCapitalMember2022-06-30 0000766792us-gaap:CommonStockMember2022-06-30 0000766792us-gaap:RetainedEarningsMember2022-01-012022-06-30 0000766792us-gaap:AdditionalPaidInCapitalMember2022-01-012022-06-30 0000766792us-gaap:CommonStockMember2022-01-012022-06-30 0000766792us-gaap:RetainedEarningsMember2021-12-31 0000766792us-gaap:AdditionalPaidInCapitalMember2021-12-31 0000766792us-gaap:CommonStockMember2021-12-31 0000766792us-gaap:RetainedEarningsMember2023-06-30 0000766792us-gaap:AdditionalPaidInCapitalMember2023-06-30 0000766792us-gaap:CommonStockMember2023-06-30 0000766792us-gaap:RetainedEarningsMember2023-01-012023-06-30 0000766792us-gaap:AdditionalPaidInCapitalMember2023-01-012023-06-30 0000766792us-gaap:CommonStockMember2023-01-012023-06-30 0000766792us-gaap:RetainedEarningsMember2022-12-31 0000766792us-gaap:AdditionalPaidInCapitalMember2022-12-31 0000766792us-gaap:CommonStockMember2022-12-31 0000766792us-gaap:RetainedEarningsMember2022-04-012022-06-30 0000766792us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-30 0000766792us-gaap:CommonStockMember2022-04-012022-06-30 00007667922022-03-31 0000766792us-gaap:RetainedEarningsMember2022-03-31 0000766792us-gaap:AdditionalPaidInCapitalMember2022-03-31 0000766792us-gaap:CommonStockMember2022-03-31 0000766792us-gaap:RetainedEarningsMember2023-04-012023-06-30 0000766792us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-30 0000766792us-gaap:CommonStockMember2023-04-012023-06-30 0000766792us-gaap:RetainedEarningsMember2023-03-31 0000766792us-gaap:AdditionalPaidInCapitalMember2023-03-31 0000766792us-gaap:CommonStockMember2023-03-31 00007667922023-08-08
 

 


UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________

 

Form 10-Q

 

(Mark One)

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

 

For the quarterly period ended June 30, 2023

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

 

For the transition period from ____ to _____

Commission file number: 1-16525

 

CVD EQUIPMENT CORPORATION

(Name of Registrant in Its Charter)

 

New York

11-2621692

State or Other Jurisdiction of
Incorporation or Organization)

(I.R.S. Employer Identification No.)

 

355 South Technology Drive Central Islip, New York 11722

(Address of principal executive offices)

 

(631) 981-7081
(Registrants Telephone Number, Including Area Code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock

CVV

NASDAQ Capital Market

 

Indicate by check whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐

 

Indicate by check mark whether registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act).

 

Large accelerated filer ☐ Accelerated filer ☐   
Non-accelerated filer Smaller reporting company           Emerging growth company  

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.         ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).   Yes  No ☑

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 6,814,047 shares of Common Stock, $0.01 par value at August 8, 2023.

 

 

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

 

Index

 

 

Part I - Financial Information  
   

            Item 1 – Condensed Consolidated Financial Statements (Unaudited)

 
   

                           Condensed Consolidated Balance Sheets at June 30, 2023 and December 31, 2022

3

   

                           Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2023 and 2022

4

   
                           Condensed Consolidated Statements of Changes in Stockholders’ Equity for the three and six months ended June 30, 2023 and 2022 5
   
                           Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2023 and 2022 6
   

                           Notes to Condensed Consolidated Financial Statements

   7

   

            Item 2 – Management's Discussion and Analysis of Financial Condition and Results of Operations

21

            Item 3 – Quantitative and Qualitative Disclosures About Market Risk

33

            Item 4 – Controls and Procedures

33

   

Part II - Other Information

 
   

Item 1 – Legal Proceedings

35

Item 1A-Risk Factors

35

Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds

35

Item 3 – Defaults Upon Senior Securities

35

Item 4 – Mine Safety Disclosures

35

Item 5 – Other Information

35

Item 6 – Exhibits

36

   

Signatures

37

 

2

 

 

PART 1 – FINANCIAL INFORMATION

Item 1 – Financial Statements

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(in thousands, except share amounts)

(Unaudited)

 

   

June 30, 2023

   

December 31, 2022

 
ASSETS                
Current assets                

Cash and cash equivalents

  $ 13,033     $ 14,365  

Accounts receivable, net

    2,156       3,788  

Contract assets

    2,951       2,170  

Inventories, net

    4,150       2,538  

Employee retention credit receivable

    1,529       -  

Other current assets

    543       797  

Total current assets

    24,362       23,658  
                 

Employee retention credit receivable

    -       1,529  

Property, plant and equipment, net

    12,300       12,596  

Intangible assets, net

    111       119  

Other assets

    10       10  

Total assets

  $ 36,783     $ 37,912  
                 
                 
LIABILITIES AND STOCKHOLDERS EQUITY                
Current liabilities                

Accounts payable

  $ 1,307     $ 1,454  

Accrued expenses

    1,667       2,591  

Current maturities of long-term debt

    79       77  

Contract liabilities

    4,702       4,042  

Total current liabilities

    7,755       8,164  
                 

Long-term debt, net of current portion

    309       349  
                 

Total liabilities

    8,064       8,513  
                 
Stockholders’ equity:

Common stock - $0.01 par value – 20,000,000 shares authorized; issued and outstanding 6,779,063 at June 30, 2023 and 6,760,938 at December 31, 2022

    67       67  
Additional paid-in capital     28,185       27,712  

Retained earnings

    467       1,620  

Total stockholders’ equity

    28,719       29,399  
                 

Total liabilities and stockholders’ equity

  $ 36,783     $ 37,912  

 

The accompanying notes are an integral part of these condensed consolidated financial statements

 

3

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

Condensed Consolidated Statements of Operations

(in thousands, except per share and share amounts)

(Unaudited)

 

   

Three months ended

   

Six months ended

 
   

June 30,

   

June 30,

 
   

2023

   

2022

   

2023

   

2022

 
                                 

Revenue

  $ 5,069     $ 5,809     $ 13,764     $ 10,461  

Cost of revenue

    3,681       4,368       9,943       8,254  
                                 

Gross profit

    1,388       1,441       3,821       2,207  
                                 
Operating expenses                                

Research and development

    559       569       1,161       879  

Selling and shipping

    428       332       847       605  

General and administrative

    1,360       1,287       2,960       2,443  

Loss on disposition of Tantaline

    162       -       162       -  

Impairment charge

    111       -       111       -  
                                 
Total operating expenses     2,620       2,188       5,241       3,927  
                                 

Operating loss

    (1,232 )     (747 )     (1,420 )     (1,720 )
                                 

Other income (expense):

                               

Interest income

    107       13       227       31  

Interest expense

    (6 )     -       (12 )     (5 )

Foreign exchange income (expense)

    15       (110 )     43       (147 )

Other income

    13       6       20       5  

Total other income, net

    129       (91 )     278       (116 )
                                 

Loss before income tax

    (1,103 )     (838 )     (1,142 )     (1,836 )
                                 

Income tax expense

    10       1       11       1  
                                 

Net loss

  $ (1,113 )   $ (839 )   $ (1,153 )   $ (1,837 )
                                 

Loss per common share - basic

  $ (0.16 )   $ (0.12 )   $ (0.17 )   $ (0.27 )

Loss per common share - diluted

  $ (0.16 )   $ (0.12 )   $ (0.17 )   $ (0.27 )
                                 
Weighted average common shares                                

Basic

    6,778,754       6,728,938       6,776,035       6,726,990  

Diluted

    6,778,754       6,728,938       6,776,035       6,726,990  

 

The accompanying notes are an integral part of these condensed consolidated financial statements

 

4

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

Condensed Consolidated Statements of Changes in Stockholders’ Equity

(in thousands, except share amounts)

(Unaudited)

 

Three months ended June 30, 2023 and 2022

                                 
   

Common stock

                         
   

Shares

   

Par Value

   

Additional paid-in Capital

   

Retained Earnings

   

Total

 
                                         

Balance at April 1, 2023

    6,778,438     $ 67     $ 27,920     $ 1,580     $ 29,567  

Net loss

    -       -       -       (1,113 )     (1,113 )

Stock-based compensation

    -       -       262       -       262  

Exercise of stock options and issuance of shares

    625       -       3       -       3  

Balance at June 30, 2023

    6,779,063     $ 67     $ 28,185     $ 467     $ 28,719  
                                         

Balance at April 1, 2022

    6,728,938     $ 67     $ 27,374     $ 846     $ 28,287  

Net loss

    -       -       -       (839 )     (839 )

Stock-based compensation

    -       -       92       -       92  

Balance at June 30, 2022

    6,728,938     $ 67     $ 27,466     $ 7     $ 27,540  

 

Six months ended June 30, 2023 and 2022

                                 
   

Common stock

                         
   

Shares

   

Par Value

   

Additional paid-in Capital

   

Retained Earnings

   

Total

 
                                         

Balance at January 1, 2023

    6,760,938     $ 67     $ 27,712     $ 1,620     $ 29,399  

Net loss

    -       -       -       (1,153 )     (1,153 )

Stock-based compensation

    -       -       397       -       397  

Exercise of stock options and issuance of shares

    18,125       -       76       -       76  

Balance at June 30, 2023

    6,779,063     $ 67     $ 28,185     $ 467     $ 28,719  
                                         

Balance at January 1, 2022

    6,723,438     $ 67     $ 27,277     $ 1,844     $ 29,188  

Net loss

    -       -       -       (1,837 )     (1,837 )

Stock-based compensation

    5,500       -       189       -       189  

Balance at June 30, 2022

    6,728,938     $ 67     $ 27,466     $ 7     $ 27,540  

 

The accompanying notes are an integral part of these condensed consolidated financial statements

 

5

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

(in thousands)

(Unaudited)

 

   

Six months ended

 
   

June 30,

 
   

2023

   

2022

 
Cash flows from operating activities:                

Net loss

  $ (1,153 )   $ (1,837 )
Adjustments to reconcile net loss to net cash used in operating activities:                

Loss on disposition of Tantaline

    162       -  

Impairment charge

    111          
Stock-based compensation     397       189  

Depreciation and amortization

    392       402  

Changes in assets and liabilities, net of effects of disposition of Tantaline:

               

Accounts receivable

    1,592       (1,126 )

Contract assets

    (781 )     (1,717 )

Inventories

    (1,616 )     (825 )

Tax receivable

    -       716  

Other current assets

    231       (35 )

Accounts payable

    (57 )     261  
Accrued expenses     (770 )     98  

Contract liabilities

    659       1,645  
Net cash used in operating activities     (833 )     (2,229 )
                 
Cash flows from investing activities:                

Net cash used in connection with disposition of Tantaline

    (312 )     -  

Purchases of property and equipment

    (225 )     (460 )

Capitalized patents costs

    -       (47 )

Net proceeds from sale of assets

    -       10  
Net cash used in investing activities     (537 )     (497 )
                 

Cash flows from financing activities

               
Proceeds from exercise of stock options     76       -  

Payments of long-term debt

    (38 )     (1,766 )

Net cash provided by (used in) financing activities

    38       (1,766 )
                 

Net decrease in cash and cash equivalents

    (1,332 )     (4,492 )
                 

Cash and cash equivalents at beginning of period

    14,365       16,651  
                 

Cash and cash equivalents at end of period

  $ 13,033     $ 12,159  
                 

Supplemental disclosure of cash flow information:

               
                 

Income taxes paid

  $ 11     $ -  

Interest paid

  $ 12     $ 8  

 

The accompanying notes are an integral part of these condensed consolidated financial statements

 

6

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

 

NOTE 1: BASIS OF PRESENTATION

 

The accompanying unaudited condensed consolidated financial statements for CVD Equipment Corporation and Subsidiaries (collectively “the Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. They do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary in order to make the interim financials not misleading have been included and all such adjustments are of a normal recurring nature. The operating results for the three and six months ended June 30, 2023 are not necessarily indicative of the results that can be expected for the year ending December 31, 2023.

 

The condensed consolidated balance sheet as of December 31, 2022 has been derived from the audited consolidated financial statements at such date, as filed on Form 10-K with the SEC on March 27, 2023, but does not contain all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. These unaudited condensed consolidated financial statements should be read in conjunction with that report.

 

All material intercompany balances and transactions have been eliminated in consolidation.

 

Reclassifications

 

Certain reclassifications have been made to the prior period condensed consolidated financial statements to conform to the current period presentation. These reclassifications had no effect on net income (loss).

 

Liquidity

 

At June 30, 2023, the Company had $13.0 million in cash and cash equivalents. The Company anticipates that the existing cash and cash equivalents balance together with potential future income from operations, collections of existing accounts receivable, revenue from its existing backlog of products as of this filing date, the sale of inventory on hand, deposits and down payments against significant orders will be adequate to meet its working capital and capital equipment requirements, and its anticipated cash needs over the next 12 months from the date of issuance of the accompanying Form 10-Q.

 

7

 

 

NOTE 2: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Revenue Recognition

 

In accordance with FASB ASC 606 - Revenue from Contracts with Customers ("ASC 606"), the Company records revenue in an amount that reflects the consideration to which the Company expects to be entitled in exchange for goods or services promised to its customers. Under ASC 606, the Company follows a five-step model to: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price for the contract; (4) allocate the transaction price to the performance obligations; and (5) recognize revenue using one of the following two methods:

 

Over time

 

The Company designs, manufactures and sells custom chemical vapor deposition equipment through contractual agreements. These system sales require the Company to deliver functioning equipment that is generally completed within two to eighteen months from commencement of order acceptance. For systems sales that meet the criteria to recognize revenue over time, the Company recognizes revenue over time by using an input method based on costs incurred as it depicts the Company’s progress toward satisfaction of the performance obligation. For system sales that to not meet the criteria to recognize revenue over time based on the contract provisions, the Company recognize revenue based on point in time as discussed below.

 

Under this method, revenue arising from fixed price contracts is recognized as work is performed based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligations. Incurred costs include all direct material and labor costs and those indirect costs related to contract performance, such as supplies, tools, repairs and depreciation costs. Contract material costs are included in incurred costs when the project materials have been purchased or moved to work in process, and installed, as required by the project’s engineering design. Cost based input methods of revenue recognition require the Company to make estimates of costs to complete the projects. In making such estimates, significant judgment is required to evaluate assumptions related to the costs to complete the projects, including materials, labor and other system costs. If the estimated total costs on any contract are greater than the net contract revenues, the Company recognizes the entire estimated loss in the period the loss becomes known and can be reasonably estimated. There were no material impairment losses recognized on contract assets during the three and six months ended June 30, 2023 and 2022.

 

The timing of revenue recognition, billings and collections results in accounts receivables, unbilled receivables or contract assets and contract liabilities on our consolidated balance sheet. Under typical payment terms for our contracts accounted for over time, amounts are billed as work progresses in accordance with agreed-upon contractual terms, either at periodic intervals or upon achievement of contractual milestones.

 

8

 

NOTE 2: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

 

Under ASC 606, payments received from customers in excess of revenue recognized to-date results in a contract liability. These contract liabilities are not considered to represent a significant financing component of the contract because we believe these cash advances and deposits are generally used to meet working capital demands which can be higher in the earlier stages of a contract. Also, advanced payments and deposits provide us with some measure of assurance that the customer will perform on its obligations under the contract.

 

Contract assets include unbilled amounts typically resulting from system sales under contracts and represents revenue recognized that exceeds the amount billed to the customer.

 

Contract liabilities include advance payments and billings in excess of revenue recognized. The Company typically receives down payments upon receipt of order and progress payments as the system is manufactured.

 

Contract assets and contract liabilities are classified as current as these contracts in progress are expected to be substantially completed within the next twelve months.

 

Point in time

 

For non-system sales of products and services, revenue is recognized at the point in time when control of the promised products or services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those products or services (the transaction price). A performance obligation is a promise in a contract to transfer a distinct product or service to a customer and is the unit of account under ASC 606, “Revenue from Contracts with Customers”.

 

For any system equipment sales where the equipment would have an alternative use or where the contract provisions of the contract preclude the use of over time revenue recognition, revenue is recognized at the point in time when control of the equipment is transferred to the customer. For the three and six months ended June 30, 2023 and 2022, all system equipment sales were recorded over time by using an input method except for one system equipment contract in 2023 where the revenue will be recognized at the point in time when the equipment is transferred to the customer.

 

Inventories

 

Inventories are valued at the lower of cost (determined on the first-in, first-out method) or net realizable value.

 

9

 

NOTE 2: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

 

Product Warranty

 

The Company typically provides standard warranty coverage on its systems for one year from the date of final acceptance or fifteen months from the date of shipment by providing labor and parts necessary to repair the systems during the warranty period. The Company records the estimated warranty cost when revenue is recognized on the related system. Warranty cost is included in “Cost of revenue” in the condensed consolidated statements of operations. The estimated warranty cost is based on the Company’s historical cost. The Company updates its warranty estimates based on actual costs incurred.

 

Recent Accounting Standards

 

In June 2016, the FASB issued Accounting Standard Update (“ASU”) 2016-13, Financial Instruments – Credit Losses (Topic 326), which require that financial assets measured at amortized cost be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset to present the net carrying value at the amount expected to be collected. The income statement reflects the measurement of credit losses for newly recognized financial assets, as well as the increase or decreases of expected credit losses that have taken place during the period. The measurement of expected credit losses is based upon historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. On November 15, 2019, the FASB delayed the effective date for smaller reporting companies. The amendments in this update are effective for fiscal years beginning after December 15, 2022 and interim periods within those annual periods. The adoption of the ASU 2016-3 as of January 1, 2023 did not have a material impact on the Company’s financial position.

 

The Company believes there is no additional new accounting guidance adopted, but not yet effective that is relevant to the readers of its financial statements. However, there are numerous new proposals under development which, if and when enacted, may have a significant impact on our financial reporting.

 

 

NOTE 3: CONCENTRATION OF CREDIT RISK

 

Cash and cash equivalents

 

The Company had cash and cash equivalents of $13.0 million and $14.4 million at June 30, 2023 and December 31, 2022, respectively. The Company invests excess cash in U.S. treasury bills, certificates of deposit or deposit accounts, all with maturities of less than three months. Cash equivalents consisting of U.S. treasury bills were $10.0 million and $11.7 million at June 30, 2023 and December 31, 2022, respectively.

 

10

 

NOTE 3: CONCENTRATION OF CREDIT RISK (continued)

 

The Company places most of its temporary cash investments in the United States with financial institutions, which from time to time may exceed the Federal Deposit Insurance Corporation limit. The amount at risk at June 30, 2023 and December 31, 2022 was $2.6 million and $1.5 million, respectively. The Company’s cash balance at its Tantaline subsidiary based in Denmark exceeded the government guarantee limit by approximately $0.5 million at December 31, 2022.

 

Account receivable

 

The Company sells products and services to various companies across several industries in the ordinary course of business. The Company performs ongoing credit evaluations to assess the probability of accounts receivable collection based on a number of factors, including past transaction experience, evaluation of their credit history and review of the invoicing terms of the contract to determine the financial strength of its customers.

 

Accounts receivable are presented net of an allowance for doubtful accounts of approximately $36,000 at both June 30, 2023 and December 31, 2022. The allowance is based on prior experience and management’s evaluation of the collectability of accounts receivable. Measurement of credit losses requires consideration of historical loss experience, including the need to adjust for changing business conditions, and judgments about the probable effects of relevant observable data, including present economic conditions such as delinquency rates and the financial health of specific customers. Future changes to the estimated allowance for doubtful accounts could be material to our results of operations and financial condition.

 

At June 30, 2023, the accounts receivable balance included amounts from two customers that totaled 46% of total accounts receivable and at December 31, 2022, the accounts receivable balance included amounts from two customers that totaled 66% of total accounts receivable.

 

Sales concentration

 

Revenue from a single customer in any one period can exceed 10% of our total revenues. During the three months ended June 30, 2023, four customers exceeded 10% of revenues, representing 16%, 16%, 11% and 10% of revenues, and during the six months ended June 30, 2023, two customers exceeded 10%, representing 21% and 16% of revenues.

 

During the three months ended June 30, 2022, two customers exceeded 10% of revenues, representing 24% and 15% of revenues, and during the six months ended June 30, 2022, two customers exceeded 10%, representing 16% and 12% of revenues.

 

11

 

 

NOTE 4: REVENUE RECOGNITION

 

The following table represents a disaggregation of revenue for the three and six months ended June 30, 2023 and 2022 (in thousands):

 

   

Three months ended June 30, 2023

 
                         
   

Over time

   

Point in time

   

Total

 

Energy

  $ 760     $ 38     $ 798  

Aerospace

    -       604       604  

Industrial

    1,085       915       2,000  

Research

    1,184       483       1,667  

Total

  $ 3,029     $ 2,040     $ 5,069  

 

   

Three months ended June 30, 2022

 
                         
   

Over time

   

Point in time

   

Total

 

Energy

  $ 2,024     $ 219     $ 2,243  

Aerospace

    -       520       520  

Industrial

    1,450       725       2,175  

Research

    299       572       871  

Total

  $ 3,773     $ 2,036     $ 5,809  

 

   

Six months ended June 30, 2023

 
                         
   

Over time

   

Point in time

   

Total

 

Energy

  $ 3,276     $ 52     $ 3,328  

Aerospace

    264       855       1,119  

Industrial

    4,756       1,127       5,883  

Research

    2,456       978       3,434  

Total

  $ 10,752     $ 3,012     $ 13,764  

 

   

Six months ended June 30, 2022

 
                         
   

Over time

   

Point in time

   

Total

 

Energy

  $ 2,923     $ 226     $ 3.149  

Aerospace

    -       1,221       1,221  

Industrial

    2,446       1,597       4,043  

Research

    1,005       1,043       2,048  

Total

  $ 6,374     $ 4,087     $ 10,461  

 

12

 

NOTE 4: REVENUE RECOGNITION (continued)

 

The energy market includes customers involved in the manufacture of silicon carbide wafers and batteries. Aerospace market includes customers that manufacture aircraft engines. Industrial end market consists of various end customers in diverse industries. Research market principally represents customers that are universities and other research institutions.

 

The Company has unrecognized contract revenue of approximately $4.5 million at June 30, 2023, which it expects to substantially recognize as revenue within the next twelve months based on over time revenue recognition. The Company also has orders of approximately $12.1 million for equipment contracts that it expects to recognize with the next twelve months based on point in time revenue recognition.

 

Judgment is required to evaluate assumptions including the amount of net contract revenues and the total estimated costs to determine our progress towards contract completion and to calculate the corresponding amount of revenue to recognize.

 

Changes in estimates for sales of systems may occur for a variety of reasons, including but not limited to (i) build accelerations or delays, (ii) product cost forecast changes, (iii) cost related change orders or add-ons, or (iv) changes in other information used to estimate costs. Changes in estimates may have a material effect on the Company’s Consolidated Statements of Operations.

 

Contract assets and liabilities

 

Contract assets and contract liabilities on input method type contracts in progress are summarized as follows as of June 30, 2023 (in thousands):

 

Costs incurred on contracts in progress

  $ 14,062  

Estimated earnings

    9,975  
      24,037  

Billings to date

    (25,525 )
      (1,488 )
Deferred revenue related to non-system contracts     (263 )
    $ (1,751 )
         

Included in accompanying condensed consolidated balance sheet as of June 30, 2023 under the following captions (in thousands):

       

Contract assets

  $ 2,951  
Contract liabilities   $ 4,702  

 

Of the contract liability balances at December 31, 2022 and 2021 of $4.0 million and $1.7 million, respectively, $2.6 million and $1.6 million was recognized as revenue during the six months ended June 30, 2023 and 2022, respectively.

 

13

 

 

 

NOTE 5: INVENTORIES, NET

 

Inventories consist of:

               
   

June 30, 2023

    December 31, 2022  
                 

Raw materials

  $ 2,543     $ 2,165  

Work-in-process

    1,607       373  

Total

  $ 4,150     $ 2,538  

 

 

NOTE 6: LONG-TERM DEBT

 

In September 2022, the Company entered into a loan agreement to fund the acquisition of machinery. The loan amount of $432,000, is payable in 60 equal monthly installments of $8,352 and secured by equipment. The interest rate is 6%.

 

 

NOTE 7: EARNINGS PER SHARE

 

The calculation of basic and diluted weighted average common shares outstanding for the three and six months ended June 30, 2023 and 2022 is as follows:

 

   

Three months ended

June 30,

   

Six months ended

June 30,

 
   

2023

   

2022

   

2023

   

2022

 
                                 

Basic weighted average common shares outstanding

    6,778,754       6,728,938       6,776,035       6,726,990  

Dilutive effect of options and unvested restricted stock

    -       -       -       -  

Diluted weighted average shares outstanding

    6,778,754       6,728,938       6,776,035       6,726,990  

 

14

 

NOTE 7: EARNINGS PER SHARE (continued)

 

At June 30, 2023, stock options to purchase 905,125 shares of common stock were outstanding and 273,000 were exercisable. At June 30, 2022, stock options to purchase 599,500 shares of common stock were outstanding and 297,500 were exercisable.

 

For the three and six months ended June 30, 2023 and 2022, all stock options were excluded in the computation of diluted earnings per share because their effect was antidilutive.

 

 

NOTE 8: STOCK-BASED COMPENSATION EXPENSE

 

The Company recorded stock-based compensation for the three and six months ended June 30, 2023 and 2022, respectively, that were included in the following line items in our Consolidated Statements of Operations (in thousands):

 

   

Three months ended June 30,

   

Six months ended June 30,

 
   

2023

   

2022

   

2023

   

2022

 
                                 

Cost of revenue

  $ 41     $ 9     $ 60     $ 17  

Research and development

    45       13       65       26  

Selling

    31       5       42       11  

General and administrative

    145       65       230       135  
                                 

Total

  $ 262     $ 92     $ 397     $ 189  

 

Stock-based compensation expense in both three month periods ended June 30, 2023 and 2022 included approximately $40,000 related to restricted stock awards that directors are entitled to receive pursuant to the Director Compensation plan. Stock-based compensation expense in both six month periods ended June 30, 2023 and 2022 included approximately $80,000 related to restricted stock awards that directors are entitled to receive pursuant to the Director Compensation plan. Under this plan each of the four independent directors is entitled to an Annual Equity Retainer in the amount of $40,000, to be granted on the date of the Company’s annual meeting of shareholders.

 

For the six months ended June 30, 2023, the Company granted 254,000 stock options, vesting 25% per year over four years, with a ten-year life. The Company determined the weighted average fair value of stock options granted was $9.27 and is based upon weighted average assumptions below.

 

Stock price

  $ 14.02  

Exercise price

  $ 14.02  

Dividend yield

    0 %

Expected volatility

    72 %

Risk-free interest rate

    3.39 %

Expected life (in years)

    6.00  

 

15

 

NOTE 8: STOCK-BASED COMPENSATION EXPENSE (continued)

 

The following table summarizes stock options awards through June 30, 2023:

 

           

Weighted

 
   

Stock Option

   

Average

 
   

Awards

   

Exercise

 
   

(in shares)

   

Price

 

Outstanding at January 1, 2023

    673,000     $ 5.70  

Granted

    244,000       14.11  

Exercised

    (17,500 )     4.19  
                 

Outstanding at March 31, 2023

    899,500       8.01  

Granted

    10,000       11.87  

Exercised

    (625 )     4.71  

Forfeited

    (3,750 )     4.01  

Outstanding at June 30, 2023

    905,125     $ 8.07  

 

The following table summarizes information about the outstanding and exercisable options at June 30, 2023 by ranges of exercise prices:

 

         

Options Outstanding

   

Options Exercisable

 
                 

Weighted

   

Weighted

                   

Weighted

         
                 

Average

   

Average

                   

Average

         

Exercise

   

Number

   

Remaining

   

Exercise

   

Intrinsic

   

Number

   

Exercise

   

Intrinsic

 

Price Range

   

Outstanding

   

Contractual

   

Price

   

Value

   

Exercisable

   

Price

   

Value

 
$4.00 - 7.00       511,125       8.3     $ 4.55     $ 1,443,308       133,000     $ 4.45     $ 388,093  
$7.01 - 10.00       20,000       4.8     $ 8.07     $ -       20,000     $ 8.07     $ -  
$10.01 - 13.00       130,000       4.5     $ 11.51     $ -       120,000     $ 10.52     $ -  
$13.01 - 16.00       244,000       9.7     $ 14.11     $ -       -       -     $ -  

 

As of June 30, 2023, there was $3.0 million of unrecognized compensation costs related to stock options expected to be recognized over a weighted average period of 3.4 years.

 

 

NOTE 9: INCOME TAXES

 

As of June 30, 2023 and December 31, 2022, the Company has provided a full valuation allowance against its net deferred tax assets. This was based on management’s assessment, including the last four years of operating losses, that it is more likely than not that the net deferred tax assets may not be realized in the future. Management continues to evaluate for potential utilization of the Company’s net deferred tax asset, which has been fully reserved for, on a quarterly basis, reviewing our economic models, including projections of future operating results.

 

16

 

 

NOTE 10: SEGMENT REPORTING

 

The Company operates through three segments: CVD Equipment, Stainless Design Concepts (“SDC”) and CVD Materials. The CVD Equipment segment manufactures and sells chemical vapor deposition, physical vapor transport and similar equipment. The SDC segment designs and manufactures ultra-high purity gas and chemical delivery control systems. The CVD Materials segment provides material coatings for aerospace, medical, electronic and other applications and is not considered a core business of the Company. See Note 11 for the disposition of the Tantaline subsidiary and planned disposition of the MesoScribe subsidiary which comprise the CVD Materials segment. The Company evaluates performance based on several factors, of which the primary financial measure is income (loss) before taxes.

 

The Company’s corporate administration activities are reported in the “Corporate” column. These activities primarily include expenses related to certain corporate officers and support staff, expenses related to the Company’s Board of Directors, stock option expense for options and shares of restricted stock granted to corporate administration employees, certain consulting expenses, investor and shareholder relations activities, and all of the Company’s legal, auditing and professional fees.

 

Elimination entries included in the “Eliminations” column represent intersegment revenues and cost of revenues that are eliminated in consolidation. Intersegment sales by the SDC segment to the CVD Equipment segment for the three months ended June 30, 2023 and 2022 were $138,000 and $380,000, respectively and $266,000 and $425,000 for the six months ended June 30, 2023 and 2022, respectively. Intersegment sales by the CVD Equipment segment to the SDC segment for the three months and six months ended June 30, 2023 were $65,000. There were no intersegment sales by the CVD Equipment segment to the SDC segment in 2022.

 

The following table presents certain information regarding the Company’s segments as of and for the three months ended June 30, 2023 and 2022 (in thousands):

 

2023

                                               
   

CVD

Equipment

   

SDC

   

CVD

Materials

   

Eliminations

   

Corporate

   

Consolidated

 

Assets

  $ 32,139     $ 4,189     $ 483     $ (28 )   $ -     $ 36,783  
                                                 

Revenue

  $ 3,134     $ 1,795     $ 342     $ (202 )   $ -     $ 5,069  

Operating (loss) income

    (445 )     363       (224 ) *     (28 )     (898 )     (1,232 )

Pretax (loss) income

    (445 )     364       (203 ) *     (28 )     (791 )     (1,103 )

Depreciation and amortization

  $ 136     $ 12     $ 79     $ -     $ -     $ 227  

Purchase of property, plant & equipment

  $ 78     $ -     $ -     $ -     $ -     $ 78  

 

2022

                                               
   

CVD

Equipment

   

SDC

   

CVD

Materials

   

Eliminations

   

Corporate

   

Consolidated

 

Assets

  $ 23,661     $ 8,474     $ 1,913     $ 68     $ -     $ 34,116  
                                                 

Revenue

  $ 3,782     $ 1,591     $ 816     $ (380 )   $ -     $ 5,809  

Operating (loss) income

    (469 )     227       253       -       (758 )     (747 )

Pretax (loss) income

    (450 )     227       143       -       (758 )     (838 )

Depreciation and amortization

  $ 116     $ 12     $ 23     $ -     $ -     $ 151  

Purchase of property, plant & equipment

  $ 283     $ -     $ -     $ -     $ -     $ 283  

 

* Includes loss on sale of Tantaline of $0.2 million and impairment charge related to MesoScribe fixed assets of $0.1 million.

 

17

 

The following table presents certain information regarding the Company’s segments as of and for the six months ended June 30, 2023 and 2022 (in thousands):

 

2023

                                               
   

CVD

Equipment

   

SDC

   

CVD

Materials

   

Eliminations

   

Corporate

   

Consolidated

 
                                                 

Revenue

  $ 8,979     $ 4,107     $ 1,009     $ (331 )   $ -     $ 13,764  

Operating (loss) income

    (267 )     994       (143 ) *     (28 )     (1,976 )     (1,420 )

Pretax (loss) income

    (265 )     996       (95 ) *     (28 )     (1,750 )     (1,142 )

Depreciation and amortization

  $ 267     $ 24     $ 101     $ -     $ -     $ 392  

Purchase of property, plant & equipment

  $ 215     $ 10     $ -     $ -     $ -     $ 225  

 

2022

                                               
   

CVD

Equipment

   

SDC

   

CVD

Materials

   

Eliminations

   

Corporate

   

Consolidated

 
                                                 

Revenue

  $ 6,607     $ 3,006     $ 1,273     $ (425 )   $ -     $ 10,461  

Operating (loss) income

    (1,236 )     670       284       -       (1,438 )     (1,720 )

Pretax (loss) income

    (1,204 )     670       136       -       (1,438 )     (1,836 )

Depreciation and amortization

  $ 332     $ 25     $ 45     $ -     $ -     $ 402  

Purchase of property, plant & equipment

  $ 428     $ 2     $ 30     $ -     $ -     $ 460  

 

* Includes loss on sale of Tantaline of $0.2 million and impairment charge related to MesoScribe fixed assets of $0.1 million.

 

18

 

 

NOTE 11: CVD MATERIALS – TANTALINE AND MESOCRIBE SUBSIDIAIRES

 

Tantaline Subsidiary

 

On May 26, 2023, the Company sold its Tantaline subsidiary located in Nordborg, Denmark in exchange for a nominal amount at closing and an earn-out provision based on any net income that Tantaline may earn during the five-year period ending December 31, 2027. The Company recorded a loss of $0.2 million upon the sale. Any earn-out amounts will be recognized when and if any such amounts become probable of receipt.

 

The decision to sell Tantaline was based on the Company’s ongoing strategy to focus on the equipment business consisting of the CVD Equipment and SDC segments and reduce its focus on the non-core CVD Materials business.

 

Including the loss on disposition of $0.2 million, the revenues and net loss of Tantaline were $44,000 and $0.2 million respectively, for the three months ended June 30, 2023 and the revenues and net income of Tantaline were $0.5 million and $0.1 million, respectively, for the six months ended June 30, 2023. The total assets and total liabilities of the Tantaline subsidiary were $1.1 million and $0.4 million as of December 31, 2022.

 

19

 

NOTE 11: CVD MATERIALS – TANTALINE AND MESOCRIBE SUBSIDIAIRES (continued)

 

MesoScribe Subsidiary

 

During the three months ended June 30, 2023, the Company entered into negotiations with a third party to sell certain assets and license certain propriety information of MesoScribe.

 

On August 8, 2023, the Company entered into a Purchase and License Agreement (“the Agreement”) with the third-party. Pursuant to the Agreement, the Company will sell certain proprietary assets relating to its plasma spray technology and material deposition system and grant a non-exclusive license to use certain of the Company's related intellectual property as more fully described in the Agreement, for an aggregate purchase price of $0.9 million. The purchase price is payable in several installments and contingent upon certain performance metrics and other milestones.

 

The Company will continue to fulfill remaining orders for MesoScribe products through the end of 2023 at which time it plans to cease the remaining operations of MesoScribe and dispose of any remaining equipment. During the three and six months ended June 30, 2023, the Company recorded an impairment charge of $0.1 million for certain equipment of MesoScribe based on its decision to cease the remaining operations by the end of 2023.

 

Including the impairment charge of $0.1 million, the revenues and net income of MesoScribe were $0.3 million and $0.1 million for the three months ended June 30, 2023. The revenue and net income were $0.5 million and $0.1 million respectively, for the six months ended June 30, 2023.

 

The total assets and total liabilities of the MesoScribe subsidiary were $0.4 million and $48,000, respectively, as of June 30, 2023 and $0.8 million and $0.1 million, respectively, as of December 31, 2022.

 

 

NOTE 12: RISKS AND UNCERTAINTIES

 

The Company currently operates in a challenging economic environment as the global economy continues to confront the impacts from the pandemic, geopolitical conflicts, inflationary pressures and adverse supply chain disruptions. The specific impacts on the Company have included:

 

Significant geopolitical developments across Europe and Asia (including the war in Ukraine) have and may continue to restrict the Company’s ability to procure raw materials and components such as nickel and integrated circuits, as well as impact the Company’s ability to sell its products into China, Russia and other Eastern European and Asian regions.

 

Supply chain disruptions have led to much longer lead times to acquire raw materials for production and has led to inflationary pressures in both materials and labor. These supply chain disruptions have impacted the Company’s ability to recognize revenue more timely as it delays the Company’s manufacturing processes.

 

While management has initiated actions to mitigate the potential negative impacts to its revenue and profitability, the Company is unable to predict the impact that the above uncertainties will have on its future results of operations and cash flows.

 

20

 

 

Item 2.          Managements Discussion and Analysis of Financial Condition and Results of Operations.

 

Except for historical information contained herein, this Managements Discussion and Analysis of Financial Condition and Results of Operations contains forwardlooking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. These statements involve known and unknown risks and uncertainties that may cause our actual results or outcomes to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These forward-looking statements are based on various factors and are derived utilizing numerous important assumptions and other important factors that could cause actual results to differ materially from those in the forward-looking statements. Important assumptions and other factors that could cause actual results to differ materially from those in the forward-looking statements, include, but are not limited to:

 

 

competition in our existing and potential future product lines of business, including our PVT150 system;

 

 

our ability to attract and retain key personnel and employees;

 

 

our ability to obtain financing on acceptable terms if and when needed;

 

 

uncertainty as to our ability to develop new products for the high power electronics market including our plan to develop a PVT200 to grow silicon carbide crystals for 200mm wafters and epitaxy equipment for silicon carbide waters;

 

 

uncertainty as to our future profitability;

 

 

uncertainty as to any future expansion of the Company;

 

 

uncertainty as to our ability to adequately obtain raw materials and components from foreign markets in light of geopolitical developments, and

 

 

uncertainty as to our ability to timely acquire raw materials for production due to supply chain disruptions.

 

Other factors and assumptions not identified above were also involved in the derivation of these forward-looking statements and the failure of such assumptions to be realized as well as other factors may also cause actual results to differ materially from those projected. We assume no obligation to update these forward-looking statements to reflect actual results, changes in assumptions, or changes in other factors affecting such forward-looking statements. Past performance is no guaranty of future results.

 

21

 

You should not place undue reliance on any forward-looking statements, which speak only as of the dates they are made. When used with this Report, the words believes anticipates, expects, estimates, plans, intends, will and similar expressions are intended to identify forward-looking statements.

 

Executive Summary

 

We have served the advanced materials markets with chemical vapor and thermal process equipment for over 40 years. CVD designs, develops, and manufactures a broad range of chemical vapor deposition, thermal process, gas control, and other state-of-the-art equipment and process solutions used to develop and manufacture materials and coatings for industrial applications and research. To learn more about CVD’s systems and offerings, visit www.cvdequipment.com.

 

Business Update

 

Our core strategy is to focus on growth market applications in end-user markets related to the “electrification of everything” and aerospace. The phrase “electrification of everything” refers to the shift from fossil fuels to the use of electricity to power devices, buildings, electric vehicles or EVs, and many other applications. With respect to aerospace, our systems are being used by our customers to produce ceramic matrix composite materials or CMCs that will be used in next generation jet engines with the objective of reducing jet fuel consumption and contributing to the decarbonization of that industry.

 

During 2021, we received the first six (6) orders for our PVT150 system that is used by our customer to grow silicon carbide crystals. These crystals are then further processed into silicon carbide wafters by our customer and later processed into integrated circuits and other devices. Devices based on silicon carbide have been shown to reduce energy consumption in EVs and reduce the need for additional cooling elements. During 2022, we received an additional 24 orders from the same customer. We also launched our marketing campaign for the PVT150 in the first quarter of 2023 as we seek orders from other potential customers.

 

During 2022, we completed the production of a system for a customer that deposits coatings onto powders used in silicon-graphite anodes that has the objective of increasing EV battery performance while lowering cost.

 

We believe recent orders we received from a major aerospace company for the production of chemical vapor infiltration system reflects the beginnings of a recovery in aircraft manufacturing. In prior years, we had sold Tow-Coating Systems to manufacture CMCs to another major jet engine manufacturer and have an installed base of such systems at that customer.

 

During the six months ended June 30, 2023, new order bookings approximated $15.8 million, representing a decrease of approximately $1.0 million or 6% as compared to bookings of $16.7 million in six months ended June 30, 2022. CVD Equipment’s orders in the first half of 2023 were driven by demand in two of our three strategic markets. Aerospace attributed approximately $8.7 million of multiple systems orders during the six months ended June 30, 2023 that will ship over the next 12 months. Also contributing to the order bookings in 2023 was a battery nanomaterial production system of approximately $1.8 million.

 

22

 

Our PVT150 system which was launched in 2022 with an initial 20 systems shipped in 2022, and a follow-on order of 10 systems to the same customer of which 8 units shipped in the second quarter of 2023 and the balance will be shipped in the second half of 2023. In the first quarter of 2023, the PVT150 system was launched to the broader customer market and we are engaged in discussions with several potential customers.  There were no PVT150 orders received in the first six months of 2023. The uncertainty as to the receipt and timing of orders for our PVT150 system contributes to the overall quarter to quarter fluctuation in orders.

 

Our backlog increased from $17.8 million at December 31, 2022 to $18.8 million at June 30, 2023 as orders were in excess of revenues by approximately $2.0 million. In addition, the backlog was reduced by $0.5 million related to the sale of Tantaline and $0.6 million related to the planned wind down of MesoScribe.

 

Historically, our orders have fluctuated based on end user market conditions, adoption of our new products and acceptance of our products. The order rate as well as other factors in our manufacturing process ultimately impacts the timing of revenue recognition whether accounted for over time or at a point in time. In addition, system revenue that will be recognized based on point in time will result in fluctuations in revenue recognized at the point in time when control of the promised products or services is transferred to the Company’s customers.

 

Accordingly, orders received from customers and the corresponding revenue recognized may fluctuate from quarter to quarter.  The sales cycle for our equipment is typically six months, but can range up to twelve to eighteen months, depending on the application and product stage of the equipment. The order cycle to manufacture and test a system also will vary from six to eighteen months for our CVD Equipment segment and two to twelve months for our SDC segment, depending on system complexity and magnitude of the system.

 

23

 

Results of Operations

 

Three Months Ended June 30, 2023 and 2022

 

The following table presents revenue and expense line items reported in our Consolidated Statements of Operations for the three months ended June 30, 2023 and 2022 and the period-over-period dollar and percentage changes for those line items (in thousands, except percentages).

 

   

Three months ended

June 30

                 
   

2023

   

2022

   

Change

   

Percent

 

Revenue

  $ 5,069     $ 5,809     $ (740 )     (12.7 %)
                                 

Cost of revenue

    3,681       4,368       (687 )     (15.7 %)
                                 

Gross profit

    1,388       1,441       (53 )     (3.7

%)

Gross profit percentage

    27.4 %     24.8 %                
                                 

Operating expenses:

                               

Research and development

    559       569       (10 )     (1.8 %)

Selling

    428       332       96       28.9 %

General and administrative

    1,360       1,287       73       5.7 %

Loss on disposition of Tantaline

    162       -       162       *  

Impairment charge

    111       -       111       *  
                                 

Total operating expenses

    2,620       2,188       432       19.7 %
                                 

Operating loss

    (1,232 )     (747 )     (485 )     (64.9 %)
                                 

Other income (expense):

                               

Interest income

    107       13       94       *  

Interest expense

    (6 )     -       (6 )     *  

Foreign exchange income (expense)

    15       (110 )     125       *  

Other income

    13       6       7       *  

Total other income (expense), net

    129       (91 )     220       *  
                                 

Loss before income taxes

    (1,103 )     (838 )     (265 )     (31.6 %)
                                 

Income tax expense

    10       1       9       *  
                                 

Net loss

  $ (1,113 )   $ (839 )   $ (274 )     (32.7 %)
                                 
Revenue (net of intersegment sales)                                

CVD Equipment

  $ 3,069     $ 3,782     $ (713 )     (18.9 %)

SDC

    1,658       1,211       447       36.9 %

CVD Materials

    342       816       (474 )     (58.1 %)
                                 

Total

  $ 5,069     $ 5,809     $ (740 )     (12.7 %)

 

* Not meaningful

 

24

 

Revenue

 

Our revenue for the three months ended June 30, 2023 was $5.1 million compared to $5.8 million for the three months ended June 30, 2022, a decrease of 12.7%.

 

The decrease in revenue versus the prior year period was primarily attributable to lower revenue of $0.7 million from the CVD Equipment segment related to lower equipment revenue, a $0.4 million increase in revenue from our SDC segment and a $0.5 million decrease from the CVD Materials segment. The decrease in revenue in the period was principally the result of lower PVT equipment revenues at CVD Equipment and the sale of the Tantaline subsidiary that is part of the CVD Materials segment.

 

Our order backlog at June 30, 2023 was approximately $18.8 million as compared to $17.8 million at December 31, 2022. Our backlog at June 30, 2023 consists of $4.5 million related to remaining performance obligations of contracts in progress and not yet started, $12.1 million of system sales that will be recognized based on point in time and $2.2 million represents non-system orders received from customers. Historically, our revenues and orders have fluctuated based on changes in order rate as well as other factors in our manufacturing process that impacts the timing of revenue recognition. In addition, system revenue that will be recognized based on point in time will result in fluctuations in revenue recognized at the point in time when control of the promised products or services is transferred to the Company’s customers. Accordingly, orders received from customers and revenue recognized may fluctuate from quarter to quarter.

 

The revenue contributed by the CVD Equipment segment for the three months ended June 30, 2023 of $3.1 million represented 60.5% of overall revenue as compared to $3.8 million or 65.1% of overall revenue for the three months ended June 30, 2022. The decrease in revenues of $0.7 million or 18.9% resulted principally from less PVT150 revenues in the current quarter as compared to the prior year quarter.

 

25

 

The revenue contributed by the SDC segment for the three months ended June 30, 2023 of $1.7 million represented 32.7% of overall revenue as compared to $1.2 million or 20.8% of overall revenue for the three months ended June 30, 2022. Revenue for our SDC segment increased $0.4 million or 36.9% due to increased orders and strong demand for the SDC’s gas and chemical delivery system products as compared to the prior year. The demand and related bookings for SDC’s products are subject to fluctuation depending on changes in market demand.

 

The revenue contributed by the CVD Materials segment for the three months ended June 30, 2023 of $0.3 million represented 6.7% of our overall revenue as compared to $0.8 million or 14.0% of overall revenue for the three months ended June 30, 2022. The decline was principally due to the sale of the Tantaline subsidiary during the quarter.

 

Gross Profit

 

Gross profit for the three months ended June 30, 2023 was $1.4 million, with a gross profit margin of 27.4%, compared to a gross profit of $1.4 million and a gross profit margin of 24.8% for the three months ended June 30, 2022. The decrease in gross profit of $53,000 was primarily due to lower revenues that was offset by an improved product mix as compared to the prior period.

 

Research and Development

 

For the three months ended June 30, 2023, research and development expenses were $0.6 million, or 11.0% of revenue as compared to $0.6 million, or 9.8% for the three months ended June 30, 2022. The small decrease in 2023 was the result of lower bonus accruals that were partially offset by increased personnel and employee-related costs to develop new products for key growth markets and lower production volumes.

 

General engineering support and expenses related to the development of more standardized products and value-added development of existing products are reflected as part of research and development expense. General engineering support and expenses are charged to costs of goods sold when work is performed directly on a customer order.

 

Selling

 

Selling expenses were $0.4 million or 8.4% of the revenue for the three months ended June 30, 2023 as compared to $0.3 million or 5.7% for the three months ended June 30, 2022. The increase in 2023 was primarily the result of increased personnel and employee-related costs to support increased marketing efforts.

 

General and Administrative

 

General and administrative expenses for the three months ended June 30, 2023 were $1.4 million or 26.8% of revenue compared to $1.3 million or 22.2% of revenue for the three months ended June 30, 2022, an increase of $0.1 million. The increase in expenses was principally due increases in personnel and employee-related costs and professional fees offset by lower bonus accruals.

 

During the three months ended June 30, 2023, the Company revised its estimated bonus accrual as of June 30, 2023. This resulted in an adjustment of $0.2 million to reverse a portion of the 2023 bonus that was accrued as of March 31, 2023. The impact of this reversal on general administrative expense was a reduction of $0.1 million. The impact of this reversal also resulted in reductions of expenses for cost of revenue of $41,000, research and development of $56,000 and selling expenses of $24,000 during the three months ended June 30, 2023.

 

26

 

Loss on Disposition of Tantaline

 

This item represents the net loss on the sale of our Tantaline subsidiary including professional fees.

 

Impairment Charge

 

This item represents the loss on the impairment of certain assets of MesoScribe based on the decision at June 30, 2023 to dispose of the subsidiary in the second half of 2023.

 

Other Income (Expense), Net

 

Other income (expense), net was $129,000 for the three months ended June 30, 2023 as compared to other income (expense), net of ($91,000) for the three months ended June 30, 2022. The change was principally due to an increase in interest income due to higher interest rates and increased amounts invested in U.S. treasury bills and a reduction in the foreign exchange loss.

 

Income Taxes

 

We continue to evaluate the potential utilization of our deferred tax asset, which has been fully reserved for, on a quarterly basis, by reviewing our economic models, including projections of future operating results.

 

27

 

Six Months Ended June 30, 2023 versus June 30, 2022

 

The following table presents revenue and expense line items reported in our Consolidated Statements of Operations for the six months ended June 30, 2023 and 2022 and the period-over-period dollar and percentage changes for those line items (in thousands, except percentages).

 

   

Sic months ended

June 30

                 
   

2023

   

2022

   

Change

   

Percent

 

Revenue

  $ 13,764     $ 10,461     $ 3,303       31.6 %
                                 

Cost of revenue

    9,943       8,254       1,689       20.5 %
                                 

Gross profit

    3,821       2,207       1,614       73.1 %

Gross profit percentage

    27.8 %     21.1 %                
                                 

Operating expenses:

                               

Research and development

    1,161       879       282       32.1 %

Selling

    847       605       242       40.0 %

General and administrative

    2,960       2,443       517       21.2 %

Loss on disposition of Tantaline

    162       -       162       *  

Impairment charge

    111       -       111       *  
                                 

Total operating expenses

    5,241       3,927       1,314       33.5 %
                                 

Operating loss

    (1,420 )     (1,720 )     300       17.4 %
                                 

Other income (expense):

                               

Interest income

    227       31       196       *  

Interest expense

    (12 )     (5 )     (7 )     *  

Foreign exchange income (expense)

    43       (147 )     190       *  

Other income

    20       5       15       *  

Total other income (expense), net

    278       (116 )     394       *  
                                 

Loss before income taxes

    (1,142 )     (1,836 )     694       37.8 %
                                 

Income tax expense

    11       1       10       *  
                                 

Net loss

  $ (1,153 )   $ (1,837 )   $ 684       37.2 %
                                 
Revenue (net of intersegment sales)                                

CVD Equipment

  $ 8,914     $ 6,607     $ 2,307       34.9 %

SDC

    3,841       2,581       1,260       48.8 %

CVD Materials

    1,009       1,273       (264 )     (20.7% )
                                 

Total

  $ 13,764     $ 10,461     $ 3,303       31.6 %

 

* Not meaningful

 

28

 

Revenue

 

Our revenue for the six months ended June 30, 2023 was $13.8 million compared to $10.5 million for the six months ended June 30, 2022, an increase of 31.6%.

 

The increase in revenue versus the prior year period was primarily attributable to increased revenue of $2.3 million from the CVD Equipment segment related to equipment sales and spare parts, a $1.3 million increase in revenue from our SDC segment and a $0.3 million decrease from the CVD Materials segment. The increase in revenue in the period was principally the result of the recognition of revenue associated with additional equipment contracts and from higher PVT150 revenues. Revenue related to PVT150 systems sold to one customer represented 21.0% of our total revenues and 32.4% of CVD Equipment segment revenues during the six months ended June 30, 2023. We recognized revenue on this contract as we construct the equipment for our customer.

 

The revenue contributed by the CVD Equipment segment for the six months ended June 30, 2023 of $8.9 million represented 64.8% of overall revenue as compared to $6.6 million or 63.2% of overall revenue for the six months ended June 30, 2022. The increase in revenues of $2.3 million or 34.9% resulted principally related revenue associated additional equipment contracts and higher revenues from our PVT150 system contract.

 

The revenue contributed by the SDC segment for the six months ended June 30, 2023 of $3.8 million represented 27.9% of overall revenue as compared to $2.6 million or 24.7% of overall revenue for the six months ended June 30, 2022. Revenue for our SDC segment increased $1.3 million or 48.8% due to increased orders and strong demand for the SDC’s gas and chemical delivery system products as compared to the prior year. The demand and related bookings for SDC’s products are subject to fluctuation depending on market demand.

 

The revenue contributed by the CVD Materials segment for the six months ended June 30, 2023 of $1.0 million represented 7.3% of our overall revenue as compared to $1.3 million or 12.2% of overall revenue for the six months ended June 30, 2022. The decrease in revenue was principally due to the sale of Tantaline in May 2023.

 

29

 

Gross Profit

 

Gross profit for the six months ended June 30, 2023 was $3.8 million, with a gross profit margin of 27.8%, compared to a gross profit of $2.2 million and a gross profit margin of 21.1% for the six months ended June 30, 2022. The increase in gross profit of $1.6 million was primarily the result of leveraging fixed costs on higher sales levels and an improved product mix offset by certain component cost increases and higher compensation costs.

 

Research and Development

 

For the six months ended June 30, 2023, research and development expenses were $1.2 million, or 8.4% of revenue as compared to $0.9 million, or 8.4% for the six months ended June 30, 2022. The increase in 2023 was the result of increased personnel and employee-related costs to develop new products for key growth markets offset by lower bonus expense.

 

General engineering support and expenses related to the development of more standardized products and value-added development of existing products are reflected as part of research and development expense. General engineering support and expenses are charged to costs of goods sold when work is performed directly on a customer order.

 

Selling

 

Selling expenses were $0.8 million or 6.2% of the revenue for the six months ended June 30, 2023 as compared to $0.6 million or 5.8% for the six months ended June 30, 2022. The increase in 2023 was primarily the result of increased personnel and employee-related costs to support increased marketing efforts as well as increase in trade shows and other marketing expenses.

 

General and Administrative

 

General and administrative expenses for the six months ended June 30, 2023 were $3.0 million or 21.5% of revenue compared to $2.4 million or 23.4% of revenue for the six months ended June 30, 2022, an increase of $0.5 million. The increase in expenses was principally due to increases in personnel and employee-related costs to support the growth of our business and higher professional fees of $0.2 million offset by lower bonus expense.

 

Loss on disposition of Tantaline

 

This item represents the net loss on the sale of our Tantaline subsidiary including professional fees.

 

Impairment Charge

 

This item represents the loss on the impairment of certain assets of MesoScribe based on the decision to dispose of the subsidiary in the second half of 2023.

 

30

 

Other Income (Expense), Net

 

Other income, net was $278,000 for the six months ended June 30, 2023 as compared to other (expense), net of ($116,000) for the six months ended June 30, 2022. The change was principally due to an increase in interest income due to higher interest rates and increased amounts invested in U.S. treasury bills and a reduction in the foreign exchange loss.

 

Income Taxes

 

We continue to evaluate the potential utilization of our deferred tax asset, which has been fully reserved for, on a quarterly basis, by reviewing our economic models, including projections of future operating results.

 

Liquidity and Capital Resources

 

As of June 30, 2023, aggregate working capital was $16.6 million as compared to aggregate working capital of $15.5 million at December 31, 2022. Working capital increased due to the classification of our employee retention credit receivable as a current asset at June 30, 2023 as the receivable was fully collected in July 2023. Cash and cash equivalents at June 30, 2023 and December 31, 2022 were $13.0 million and $14.4 million, respectively.

 

Net cash used in operating activities for the six months ended June 30, 2023 was $0.8 million. This decrease was principally due to increases in contract assets of $0.8 million, increase in inventories of $1.6 million, decrease in accrued expenses of $0.8 million (primarily due to payment of 2022 bonus) offset by reduction in accounts receivable of $1.6 million, an increase in contract liabilities of $0.7 million and non-cash items of $1.1 million. The increase in inventory was related to the production of PVT150 equipment in anticipation of potential future orders and inventory associated with a system order that will be recognized at the point in time the equipment is transferred to the Company’s customer.

 

Capital expenditures for the six months ended June 30, 2023 were $0.2 million related to purchases of manufacturing equipment and building improvements. The disposition of Tantaline resulted in a cash outflow of $0.3 million based on the terms of the agreement.

 

Cash flows from financing activities for the six months ended June 30, 2023 included $0.1 million of proceeds from the exercise of employee stock options.

 

During the three months ended June 30, 2023, the Company entered into negotiations with a third party to sell certain assets and license certain propriety information of MesoScribe. On August 4, 2023, the Company entered into a Purchase and License Agreement (the “Agreement”) with the third-party. Pursuant to the Agreement, the Company will sell certain proprietary assets relating to its plasma spray technology and material deposition system and grant a non-exclusive license to use certain of the Company’s related intellectual property as more fully described in the Agreement, for an aggregate purchase price of $0.9 million. The purchase price is payable in several installments and contingent upon certain performance metrics and other milestones.

 

The Company will continue to fulfill remaining orders for MesoScribe products through the end of 2023 at which time it plans to cease the remaining operations of MesoScribe and dispose of any remaining equipment.

 

31

 

We believe that our cash and cash equivalent positions and our projected cash flow from operations will be sufficient to meet our working capital and capital expenditure requirements for the next twelve months from the filing of this Form 10-Q. We will continue to assess our operations and take actions anticipated to maintain our operating cash to support the working capital needs.

 

Critical Accounting Policies and Estimates

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Our critical estimates include accounting for certain items such as revenues on long-term contracts recognized on the input method; and the recoverable value of our long-lived assets.

 

We consider the following significant accounting policies to be critical because of their complexity and the high degree of judgment involved in maintaining them.

 

Revenue Recognition

 

We design, manufacture, and sell custom chemical vapor deposition equipment through contractual agreements. These system sales require us to deliver functioning equipment that is generally completed within two to eighteen months from commencement of order acceptance. For systems sales that meet the criteria to recognize revenue over time, we recognize revenue over time by using an input method based on costs incurred as it depicts our progress toward satisfaction of the performance obligation. Under this method, revenue arising from fixed price contracts is recognized as work is performed based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligations. For system sales that to not meet the criteria to recognize revenue over time based on the contract provisions, the Company recognize revenue based on point in time.

 

Incurred costs include all direct material and labor costs and those indirect costs related to contract performance, such as indirect labor, supplies, tools, repairs and depreciation costs. Contract material costs are included in incurred costs when the project materials have been purchased or moved to work in process as required by the project’s engineering design. Cost based input methods of revenue recognition require us to make estimates of costs to complete the projects. In making such estimates, significant judgment is required to evaluate assumptions related to the costs to complete the projects, including materials, labor, and other system costs. If the estimated total costs on any contract are greater than the net contract revenues, we recognize the entire estimated loss in the period the loss becomes known and can be reasonably estimated.

 

32

 

We have been engaged in the production and delivery of goods on a continual basis under contractual arrangements for many years. Historically, we have demonstrated an ability to accurately estimate total revenues and total expenses relating to our long-term contracts. However, there are many inherent risks and uncertainties in estimating revenues, expenses and progress toward completion, particularly on larger or longer-term contracts. If we do not estimate the total sales, related costs, and progress toward completion on such contracts, the estimated gross margins may be significantly impacted, or losses may need to be recognized in future periods. Any such resulting changes in margins or contract losses could be material to our results of operations and financial condition.

 

Long-Lived Assets

 

Long-lived assets consist primarily of property, plant and equipment. Long-lived assets are reviewed for impairment whenever events or circumstances indicate their carrying value may not be recoverable. When such events or circumstances arise, an estimate of the future undiscounted cash flows produced by the asset, or the appropriate grouping of assets, is compared to the asset’s carrying value to determine if impairment exists pursuant to the requirements of ASC 360-10-35, “Impairment or Disposal of Long-Lived Assets.” If the asset is determined to be impaired, the impairment loss is measured on the excess of its carrying value over its fair value. Assets to be disposed of are reported at the lower of their carrying value or net realizable value.

 

Item 3.                           Quantitative and Qualitative Disclosures About Market Risk

 

Not applicable.

 

Item 4.                           Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures

 

We maintain a system of disclosure controls and procedures (as defined in Rule 13a-15(e) and 13d-15(e) under the Exchange Act of 1934, as amended, (the “Exchange Act”)). As required by Rule 13a-15(b) under the Exchange Act, our management, under the direction of our Chief Executive Officer and Chief Financial Officer, reviewed and performed an evaluation of the effectiveness of design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) as of the end of the period covered by this Quarterly Report on Form 10-Q (the “Report”).

 

Based on that review and evaluation, our Chief Executive Officer and Chief Financial Officer, along with others in our management, have determined that as of the end of the period covered by this Report on Form 10-Q the disclosure controls and procedures were effective to provide reasonable assurance that such information is accumulated and communicated to our management, including our principal executive and financial officers, as appropriate to allow timely decisions regarding disclosures.

 

33

 

Changes in Internal Controls

 

There were no changes in our internal controls over financial reporting as defined in Rule 13a-15(f) or Rule 15d-15(f) under the Exchange Act that occurred during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, the internal controls over financial reporting.

 

Limitations on the Effectiveness of Controls

 

We believe that a control system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the control systems are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.

 

34

 

CVD EQUIPMENT CORPORATION

 

PART II

 

OTHER INFORMATION

 

 

Item 1.

Legal Proceedings.

 

 

None.

 

Item1 A.

Risk Factors.

 

 

There have been no other material changes to the risk factors disclosed in our Annual Report on Form 10-K as filed with the Securities and Exchange Commission on March 27, 2023.

 

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds.

 

 

None.

 

Item 3.

Defaults Upon Senior Securities.

 

 

None.

 

Item 4.

Mine Safety Disclosures.

 

 

Not applicable.

 

Item 5.

Other Information.

 

 

None.

 

35

 

Item 6.

Exhibits

 

31.1*

Certification of Emmanuel Lakios, Chief Executive Officer, dated August 14, 2023

 

31.2*

Certification of Richard Catalano, Chief Financial Officer, dated August 14, 2023

 

32.1*

Certification of Emmanuel Lakios, Chief Executive Officer, dated August 14, 2023, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

32.2*

Certification of Richard Catalano, Chief Financial Officer, dated August 14, 2023, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

101.1**

Inline XBRL Instance.

 

101.SCH**

Inline XBRL Taxonomy Extension Schema.

 

101.CAL**

Inline XBRL Taxonomy Extension Calculation.

 

101.DEF**

Inline XBRL Taxonomy Extension Definition.

 

101.LAB**

Inline XBRL Taxonomy Extension Labels.

 

101.PRE**

Inline XBRL Taxonomy Extension Presentation.

 

104

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

________________

 

* Filed herewith.

 

** Pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not to be filed or part of a registration statement of prospectus for purposes of Section 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under these sections.

 

36

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, this 14th day of August 2023.

 

 

CVD EQUIPMENT CORPORATION

 

By: /s/ Emmanuel Lakios

Emmanuel Lakios

President and Chief Executive Officer

(Principal Executive Officer)

 

By: /s/ Richard Catalano

Richard Catalano

Vice President and

Chief Financial Officer

(Principal Financial and

Accounting Officer)

 

 

 

37

Exhibit 31.1

 

Certifications of Principal Executive Officer

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, Emmanuel Lakios, certify that:

 

 

1.

I have reviewed this quarterly report on Form 10-Q of CVD Equipment Corporation;

 

 

2.

Based upon my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

 

3.

Based upon my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

 

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

 

 

a.

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b.

Designed such internal controls over financial reporting, or caused such internal controls over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c.

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d.

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

 

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrants’ board of directors (or persons performing the equivalent functions):

 

 

a.

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b.

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated: August 14, 2023

 

/s/ Emmanuel Lakios

----------------------------------------

President and Chief Executive Officer

 

 

 

 

Exhibit 31.2

 

Certifications of Principal Financial Officer

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, Richard Catalano, certify that:

 

 

1.

I have reviewed this quarterly report on Form 10-Q of CVD Equipment Corporation;

 

 

2.

Based upon my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

 

3.

Based upon my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.

 

 

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

 

 

a.

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b.

Designed such internal controls over financial reporting, or caused such internal controls over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c.

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d.

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

 

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrants’ board of directors (or persons performing the equivalent functions):

 

 

a.

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b.

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

 

Dated: August 14, 2023

 

/s/ Richard Catalano

----------------------------------------

Richard Catalano

Vice President and

Chief Financial Officer

(Principal Financial Officer)

 

 

 

 

Exhibit 32.1

 

Certification of Principal Executive Officer

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002

 

 

 

I, Emmanuel Lakios, President and Chief Executive Officer of CVD Equipment Corporation, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge, the quarterly report on Form 10-Q for the period ending June 30, 2023 of CVD Equipment Corporation (the “Form 10-Q”) fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934 and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of CVD Equipment Corporation.

 

 

Dated: August 14, 2023       /s/ Emmanuel Lakios

Emmanuel Lakios

President and Chief Executive Officer

(Principal Executive Officer)

 

 

 

 

Exhibit 32.2

 

Certification of Principal Financial Officer

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002

 

 

 

I, Richard Catalano, Chief Financial Officer of CVD Equipment Corporation, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge, the quarterly report on Form 10-Q for the period ending June 30, 2023 of CVD Equipment Corporation (the “Form 10-Q“) fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934 and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of CVD Equipment Corporation.

 

 

Dated: August 14, 2023      /s/ Richard Catalano

Richard Catalano

Vice President and

Chief Financial Officer

(Principal Financial Officer)

 

 

 

 

 

 

 
v3.23.2
Document And Entity Information - shares
6 Months Ended
Jun. 30, 2023
Aug. 08, 2023
Document Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Jun. 30, 2023  
Document Transition Report false  
Entity File Number 1-16525  
Entity Registrant Name CVD EQUIPMENT CORPORATION  
Entity Incorporation, State or Country Code NY  
Entity Tax Identification Number 11-2621692  
Entity Address, Address Line One 355 South Technology Drive  
Entity Address, City or Town Central Islip  
Entity Address, State or Province NY  
Entity Address, Postal Zip Code 11722  
City Area Code 631  
Local Phone Number 981-7081  
Title of 12(b) Security Common Stock  
Trading Symbol CVV  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding (in shares)   6,814,047
Entity Central Index Key 0000766792  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q2  
Amendment Flag false  
v3.23.2
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets    
Cash and cash equivalents $ 13,033 $ 14,365
Accounts receivable, net 2,156 3,788
Contract assets 2,951 2,170
Inventories, net 4,150 2,538
Employee retention credit receivable 1,529 0
Other current assets 543 797
Total current assets 24,362 23,658
Employee retention credit receivable 0 1,529
Property, plant and equipment, net 12,300 12,596
Intangible assets, net 111 119
Other assets 10 10
Total assets 36,783 37,912
Current liabilities    
Accounts payable 1,307 1,454
Accrued expenses 1,667 2,591
Current maturities of long-term debt 79 77
Contract liabilities 4,702 4,042
Total current liabilities 7,755 8,164
Long-term debt, net of current portion 309 349
Total liabilities 8,064 8,513
Common stock - $0.01 par value – 20,000,000 shares authorized; issued and outstanding 6,779,063 at June 30, 2023 and 6,760,938 at December 31, 2022 67 67
Additional paid-in capital 28,185 27,712
Retained earnings 467 1,620
Total stockholders’ equity 28,719 29,399
Total liabilities and stockholders’ equity $ 36,783 $ 37,912
v3.23.2
Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares
Jun. 30, 2023
Dec. 31, 2022
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 20,000,000 20,000,000
Common stock, shares outstanding (in shares) 6,779,063 6,760,938
Common stock, shares issued (in shares) 6,779,063 6,760,938
v3.23.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenue $ 5,069 $ 5,809 $ 13,764 $ 10,461
Cost of revenue 3,681 4,368 9,943 8,254
Gross profit 1,388 1,441 3,821 2,207
Operating expenses:        
Research and development 559 569 1,161 879
Selling and shipping 428 332 847 605
General and administrative 1,360 1,287 2,960 2,443
Loss on disposition of Tantaline 162 0 162 0
Impairment charge 111 0 111 0
Total operating expenses 2,620 2,188 5,241 3,927
Operating loss (1,232) (747) (1,420) [1] (1,720)
Other income (expense):        
Interest income 107 13 227 31
Interest expense (6) 0 (12) (5)
Foreign exchange income (expense) 15 (110) 43 (147)
Other income 13 6 20 5
Total other income, net 129 (91) 278 (116)
Loss before income taxes (1,103) (838) (1,142) [1] (1,836)
Income tax expense 10 1 11 1
Net loss $ (1,113) $ (839) $ (1,153) $ (1,837)
Loss per common share - basic (in dollars per share) $ (0.16) $ (0.12) $ (0.17) $ (0.27)
Loss per common share - diluted (in dollars per share) $ (0.16) $ (0.12) $ (0.17) $ (0.27)
Weighted average common shares outstanding:        
Basic (in shares) 6,778,754 6,728,938 6,776,035 6,726,990
Diluted (in shares) 6,778,754 6,728,938 6,776,035 6,726,990
[1] Includes loss on sale of Tantaline of $0.2 million and impairment charge related to MesoScribe fixed assets of $0.1 million.
v3.23.2
Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Balance (in shares) at Dec. 31, 2021 6,723,438      
Balance at Dec. 31, 2021 $ 67 $ 27,277 $ 1,844 $ 29,188
Net loss Stock-based compensation $ 0 0 (1,837) (1,837)
Stock-based compensation (in shares) 5,500      
Stock-based compensation $ 0 189 0 189
Balance (in shares) at Jun. 30, 2022 6,728,938      
Balance at Jun. 30, 2022 $ 67 27,466 7 27,540
Balance (in shares) at Mar. 31, 2022 6,728,938      
Balance at Mar. 31, 2022 $ 67 27,374 846 28,287
Net loss Stock-based compensation $ 0 0 (839) (839)
Stock-based compensation (in shares) 0      
Stock-based compensation $ 0 92 0 92
Balance (in shares) at Jun. 30, 2022 6,728,938      
Balance at Jun. 30, 2022 $ 67 27,466 7 $ 27,540
Balance (in shares) at Dec. 31, 2022 6,760,938     6,760,938
Balance at Dec. 31, 2022 $ 67 27,712 1,620 $ 29,399
Exercise of stock options and issuance of shares (in shares)       17,500
Balance (in shares) at Mar. 31, 2023 6,778,438      
Balance at Mar. 31, 2023 $ 67 27,920 1,580 $ 29,567
Balance (in shares) at Dec. 31, 2022 6,760,938     6,760,938
Balance at Dec. 31, 2022 $ 67 27,712 1,620 $ 29,399
Net loss Stock-based compensation $ 0 0 (1,153) (1,153)
Stock-based compensation (in shares) 0      
Stock-based compensation $ 0 397 0 397
Exercise of stock options and issuance of shares (in shares) 18,125      
Exercise of stock options and issuance of shares $ 0 76 0 $ 76
Balance (in shares) at Jun. 30, 2023 6,779,063     6,779,063
Balance at Jun. 30, 2023 $ 67 28,185 467 $ 28,719
Balance (in shares) at Mar. 31, 2023 6,778,438      
Balance at Mar. 31, 2023 $ 67 27,920 1,580 29,567
Net loss Stock-based compensation   0 (1,113) (1,113)
Stock-based compensation (in shares) 0      
Stock-based compensation $ 0 262 0 $ 262
Exercise of stock options and issuance of shares (in shares) 625     625
Exercise of stock options and issuance of shares $ 0 3 0 $ 3
Balance (in shares) at Jun. 30, 2023 6,779,063     6,779,063
Balance at Jun. 30, 2023 $ 67 $ 28,185 $ 467 $ 28,719
v3.23.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Cash flows from operating activities:        
Net loss $ (1,113) $ (839) $ (1,153) $ (1,837)
Adjustments to reconcile net loss to net cash used in operating activities        
Loss on disposition of Tantaline 162 0 162 0
Impairment charge 111 0 111 0
Stock-based compensation     397 189
Depreciation and amortization 227 151 392 402
Changes in assets and liabilities, net of effects of disposition of Tantaline:        
Accounts receivable     1,592 (1,126)
Contract assets     (781) (1,717)
Inventories     (1,616) (825)
Tax receivable     0 716
Other current assets     231 (35)
Accounts payable     (57) 261
Accrued expenses     (770) 98
Contract liabilities     659 1,645
Net cash used in operating activities     (833) (2,229)
Cash flows from investing activities:        
Net cash used in connection with disposition of Tantaline     (312) 0
Purchases of property and equipment (78) (283) (225) (460)
Capitalized patent costs     0 (47)
Net proceeds from sale of assets     0 10
Net cash used in investing activities     (537) (497)
Cash flows from financing activities        
Proceeds from exercise of stock options     76 0
Payments of long-term debt     (38) (1,766)
Net cash provided by (used in) financing activities     38 (1,766)
Net decrease in cash and cash equivalents     (1,332) (4,492)
Cash and cash equivalents at beginning of period     14,365 16,651
Cash and cash equivalents at end of period $ 13,033 $ 12,159 13,033 12,159
Supplemental disclosure of cash flow information:        
Income taxes paid     11 0
Interest paid     $ 12 $ 8
v3.23.2
Note 1 - Basis of Presentation
6 Months Ended
Jun. 30, 2023
Notes to Financial Statements  
Business Description and Basis of Presentation [Text Block]

NOTE 1: BASIS OF PRESENTATION

 

The accompanying unaudited condensed consolidated financial statements for CVD Equipment Corporation and Subsidiaries (collectively “the Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. They do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary in order to make the interim financials not misleading have been included and all such adjustments are of a normal recurring nature. The operating results for the three and six months ended June 30, 2023 are not necessarily indicative of the results that can be expected for the year ending December 31, 2023.

 

The condensed consolidated balance sheet as of December 31, 2022 has been derived from the audited consolidated financial statements at such date, as filed on Form 10-K with the SEC on March 27, 2023, but does not contain all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. These unaudited condensed consolidated financial statements should be read in conjunction with that report.

 

All material intercompany balances and transactions have been eliminated in consolidation.

 

Reclassifications

 

Certain reclassifications have been made to the prior period condensed consolidated financial statements to conform to the current period presentation. These reclassifications had no effect on net income (loss).

 

Liquidity

 

At June 30, 2023, the Company had $13.0 million in cash and cash equivalents. The Company anticipates that the existing cash and cash equivalents balance together with potential future income from operations, collections of existing accounts receivable, revenue from its existing backlog of products as of this filing date, the sale of inventory on hand, deposits and down payments against significant orders will be adequate to meet its working capital and capital equipment requirements, and its anticipated cash needs over the next 12 months from the date of issuance of the accompanying Form 10-Q.

 

v3.23.2
Note 2 - Summary of Significant Accounting Policies
6 Months Ended
Jun. 30, 2023
Notes to Financial Statements  
Significant Accounting Policies [Text Block]

NOTE 2: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Revenue Recognition

 

In accordance with FASB ASC 606 - Revenue from Contracts with Customers ("ASC 606"), the Company records revenue in an amount that reflects the consideration to which the Company expects to be entitled in exchange for goods or services promised to its customers. Under ASC 606, the Company follows a five-step model to: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price for the contract; (4) allocate the transaction price to the performance obligations; and (5) recognize revenue using one of the following two methods:

 

Over time

 

The Company designs, manufactures and sells custom chemical vapor deposition equipment through contractual agreements. These system sales require the Company to deliver functioning equipment that is generally completed within two to eighteen months from commencement of order acceptance. For systems sales that meet the criteria to recognize revenue over time, the Company recognizes revenue over time by using an input method based on costs incurred as it depicts the Company’s progress toward satisfaction of the performance obligation. For system sales that to not meet the criteria to recognize revenue over time based on the contract provisions, the Company recognize revenue based on point in time as discussed below.

 

Under this method, revenue arising from fixed price contracts is recognized as work is performed based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligations. Incurred costs include all direct material and labor costs and those indirect costs related to contract performance, such as supplies, tools, repairs and depreciation costs. Contract material costs are included in incurred costs when the project materials have been purchased or moved to work in process, and installed, as required by the project’s engineering design. Cost based input methods of revenue recognition require the Company to make estimates of costs to complete the projects. In making such estimates, significant judgment is required to evaluate assumptions related to the costs to complete the projects, including materials, labor and other system costs. If the estimated total costs on any contract are greater than the net contract revenues, the Company recognizes the entire estimated loss in the period the loss becomes known and can be reasonably estimated. There were no material impairment losses recognized on contract assets during the three and six months ended June 30, 2023 and 2022.

 

The timing of revenue recognition, billings and collections results in accounts receivables, unbilled receivables or contract assets and contract liabilities on our consolidated balance sheet. Under typical payment terms for our contracts accounted for over time, amounts are billed as work progresses in accordance with agreed-upon contractual terms, either at periodic intervals or upon achievement of contractual milestones.

 

Under ASC 606, payments received from customers in excess of revenue recognized to-date results in a contract liability. These contract liabilities are not considered to represent a significant financing component of the contract because we believe these cash advances and deposits are generally used to meet working capital demands which can be higher in the earlier stages of a contract. Also, advanced payments and deposits provide us with some measure of assurance that the customer will perform on its obligations under the contract.

 

Contract assets include unbilled amounts typically resulting from system sales under contracts and represents revenue recognized that exceeds the amount billed to the customer.

 

Contract liabilities include advance payments and billings in excess of revenue recognized. The Company typically receives down payments upon receipt of order and progress payments as the system is manufactured.

 

Contract assets and contract liabilities are classified as current as these contracts in progress are expected to be substantially completed within the next twelve months.

 

Point in time

 

For non-system sales of products and services, revenue is recognized at the point in time when control of the promised products or services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those products or services (the transaction price). A performance obligation is a promise in a contract to transfer a distinct product or service to a customer and is the unit of account under ASC 606, “Revenue from Contracts with Customers”.

 

For any system equipment sales where the equipment would have an alternative use or where the contract provisions of the contract preclude the use of over time revenue recognition, revenue is recognized at the point in time when control of the equipment is transferred to the customer. For the three and six months ended June 30, 2023 and 2022, all system equipment sales were recorded over time by using an input method except for one system equipment contract in 2023 where the revenue will be recognized at the point in time when the equipment is transferred to the customer.

 

Inventories

 

Inventories are valued at the lower of cost (determined on the first-in, first-out method) or net realizable value.

 

Product Warranty

 

The Company typically provides standard warranty coverage on its systems for one year from the date of final acceptance or fifteen months from the date of shipment by providing labor and parts necessary to repair the systems during the warranty period. The Company records the estimated warranty cost when revenue is recognized on the related system. Warranty cost is included in “Cost of revenue” in the condensed consolidated statements of operations. The estimated warranty cost is based on the Company’s historical cost. The Company updates its warranty estimates based on actual costs incurred.

 

Recent Accounting Standards

 

In June 2016, the FASB issued Accounting Standard Update (“ASU”) 2016-13, Financial Instruments – Credit Losses (Topic 326), which require that financial assets measured at amortized cost be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset to present the net carrying value at the amount expected to be collected. The income statement reflects the measurement of credit losses for newly recognized financial assets, as well as the increase or decreases of expected credit losses that have taken place during the period. The measurement of expected credit losses is based upon historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. On November 15, 2019, the FASB delayed the effective date for smaller reporting companies. The amendments in this update are effective for fiscal years beginning after December 15, 2022 and interim periods within those annual periods. The adoption of the ASU 2016-3 as of January 1, 2023 did not have a material impact on the Company’s financial position.

 

The Company believes there is no additional new accounting guidance adopted, but not yet effective that is relevant to the readers of its financial statements. However, there are numerous new proposals under development which, if and when enacted, may have a significant impact on our financial reporting.

v3.23.2
Note 3 - Concentration of Credit Risk
6 Months Ended
Jun. 30, 2023
Notes to Financial Statements  
Concentration Risk Disclosure [Text Block]

NOTE 3: CONCENTRATION OF CREDIT RISK

 

Cash and cash equivalents

 

The Company had cash and cash equivalents of $13.0 million and $14.4 million at June 30, 2023 and December 31, 2022, respectively. The Company invests excess cash in U.S. treasury bills, certificates of deposit or deposit accounts, all with maturities of less than three months. Cash equivalents consisting of U.S. treasury bills were $10.0 million and $11.7 million at June 30, 2023 and December 31, 2022, respectively.

 

The Company places most of its temporary cash investments in the United States with financial institutions, which from time to time may exceed the Federal Deposit Insurance Corporation limit. The amount at risk at June 30, 2023 and December 31, 2022 was $2.6 million and $1.5 million, respectively. The Company’s cash balance at its Tantaline subsidiary based in Denmark exceeded the government guarantee limit by approximately $0.5 million at December 31, 2022.

 

Account receivable

 

The Company sells products and services to various companies across several industries in the ordinary course of business. The Company performs ongoing credit evaluations to assess the probability of accounts receivable collection based on a number of factors, including past transaction experience, evaluation of their credit history and review of the invoicing terms of the contract to determine the financial strength of its customers.

 

Accounts receivable are presented net of an allowance for doubtful accounts of approximately $36,000 at both June 30, 2023 and December 31, 2022. The allowance is based on prior experience and management’s evaluation of the collectability of accounts receivable. Measurement of credit losses requires consideration of historical loss experience, including the need to adjust for changing business conditions, and judgments about the probable effects of relevant observable data, including present economic conditions such as delinquency rates and the financial health of specific customers. Future changes to the estimated allowance for doubtful accounts could be material to our results of operations and financial condition.

 

At June 30, 2023, the accounts receivable balance included amounts from two customers that totaled 46% of total accounts receivable and at December 31, 2022, the accounts receivable balance included amounts from two customers that totaled 66% of total accounts receivable.

 

Sales concentration

 

Revenue from a single customer in any one period can exceed 10% of our total revenues. During the three months ended June 30, 2023, four customers exceeded 10% of revenues, representing 16%, 16%, 11% and 10% of revenues, and during the six months ended June 30, 2023, two customers exceeded 10%, representing 21% and 16% of revenues.

 

During the three months ended June 30, 2022, two customers exceeded 10% of revenues, representing 24% and 15% of revenues, and during the six months ended June 30, 2022, two customers exceeded 10%, representing 16% and 12% of revenues.

 

v3.23.2
Note 4 - Revenue Recognition
6 Months Ended
Jun. 30, 2023
Notes to Financial Statements  
Revenue from Contract with Customer [Text Block]

NOTE 4: REVENUE RECOGNITION

 

The following table represents a disaggregation of revenue for the three and six months ended June 30, 2023 and 2022 (in thousands):

 

   

Three months ended June 30, 2023

 
                         
   

Over time

   

Point in time

   

Total

 

Energy

  $ 760     $ 38     $ 798  

Aerospace

    -       604       604  

Industrial

    1,085       915       2,000  

Research

    1,184       483       1,667  

Total

  $ 3,029     $ 2,040     $ 5,069  

 

   

Three months ended June 30, 2022

 
                         
   

Over time

   

Point in time

   

Total

 

Energy

  $ 2,024     $ 219     $ 2,243  

Aerospace

    -       520       520  

Industrial

    1,450       725       2,175  

Research

    299       572       871  

Total

  $ 3,773     $ 2,036     $ 5,809  

 

   

Six months ended June 30, 2023

 
                         
   

Over time

   

Point in time

   

Total

 

Energy

  $ 3,276     $ 52     $ 3,328  

Aerospace

    264       855       1,119  

Industrial

    4,756       1,127       5,883  

Research

    2,456       978       3,434  

Total

  $ 10,752     $ 3,012     $ 13,764  

 

   

Six months ended June 30, 2022

 
                         
   

Over time

   

Point in time

   

Total

 

Energy

  $ 2,923     $ 226     $ 3.149  

Aerospace

    -       1,221       1,221  

Industrial

    2,446       1,597       4,043  

Research

    1,005       1,043       2,048  

Total

  $ 6,374     $ 4,087     $ 10,461  

 

The energy market includes customers involved in the manufacture of silicon carbide wafers and batteries. Aerospace market includes customers that manufacture aircraft engines. Industrial end market consists of various end customers in diverse industries. Research market principally represents customers that are universities and other research institutions.

 

The Company has unrecognized contract revenue of approximately $4.5 million at June 30, 2023, which it expects to substantially recognize as revenue within the next twelve months based on over time revenue recognition. The Company also has orders of approximately $12.1 million for equipment contracts that it expects to recognize with the next twelve months based on point in time revenue recognition.

 

Judgment is required to evaluate assumptions including the amount of net contract revenues and the total estimated costs to determine our progress towards contract completion and to calculate the corresponding amount of revenue to recognize.

 

Changes in estimates for sales of systems may occur for a variety of reasons, including but not limited to (i) build accelerations or delays, (ii) product cost forecast changes, (iii) cost related change orders or add-ons, or (iv) changes in other information used to estimate costs. Changes in estimates may have a material effect on the Company’s Consolidated Statements of Operations.

 

Contract assets and liabilities

 

Contract assets and contract liabilities on input method type contracts in progress are summarized as follows as of June 30, 2023 (in thousands):

 

Costs incurred on contracts in progress

  $ 14,062  

Estimated earnings

    9,975  
      24,037  

Billings to date

    (25,525 )
      (1,488 )
Deferred revenue related to non-system contracts     (263 )
    $ (1,751 )
         

Included in accompanying condensed consolidated balance sheet as of June 30, 2023 under the following captions (in thousands):

       

Contract assets

  $ 2,951  
Contract liabilities   $ 4,702  

 

Of the contract liability balances at December 31, 2022 and 2021 of $4.0 million and $1.7 million, respectively, $2.6 million and $1.6 million was recognized as revenue during the six months ended June 30, 2023 and 2022, respectively.

 

v3.23.2
Note 5 - Inventories, Net
6 Months Ended
Jun. 30, 2023
Notes to Financial Statements  
Inventory Disclosure [Text Block]

NOTE 5: INVENTORIES, NET

 

Inventories consist of:

               
   

June 30, 2023

    December 31, 2022  
                 

Raw materials

  $ 2,543     $ 2,165  

Work-in-process

    1,607       373  

Total

  $ 4,150     $ 2,538  

 

v3.23.2
Note 6 - Long-term Debt
6 Months Ended
Jun. 30, 2023
Notes to Financial Statements  
Long-Term Debt [Text Block]

NOTE 6: LONG-TERM DEBT

 

In September 2022, the Company entered into a loan agreement to fund the acquisition of machinery. The loan amount of $432,000, is payable in 60 equal monthly installments of $8,352 and secured by equipment. The interest rate is 6%.

v3.23.2
Note 7 - Earnings Per Share
6 Months Ended
Jun. 30, 2023
Notes to Financial Statements  
Earnings Per Share [Text Block]

NOTE 7: EARNINGS PER SHARE

 

The calculation of basic and diluted weighted average common shares outstanding for the three and six months ended June 30, 2023 and 2022 is as follows:

 

   

Three months ended

June 30,

   

Six months ended

June 30,

 
   

2023

   

2022

   

2023

   

2022

 
                                 

Basic weighted average common shares outstanding

    6,778,754       6,728,938       6,776,035       6,726,990  

Dilutive effect of options and unvested restricted stock

    -       -       -       -  

Diluted weighted average shares outstanding

    6,778,754       6,728,938       6,776,035       6,726,990  

 

At June 30, 2023, stock options to purchase 905,125 shares of common stock were outstanding and 273,000 were exercisable. At June 30, 2022, stock options to purchase 599,500 shares of common stock were outstanding and 297,500 were exercisable.

 

For the three and six months ended June 30, 2023 and 2022, all stock options were excluded in the computation of diluted earnings per share because their effect was antidilutive.

v3.23.2
Note 8 - Stock-based Compensation Expense
6 Months Ended
Jun. 30, 2023
Notes to Financial Statements  
Share-Based Payment Arrangement [Text Block]

NOTE 8: STOCK-BASED COMPENSATION EXPENSE

 

The Company recorded stock-based compensation for the three and six months ended June 30, 2023 and 2022, respectively, that were included in the following line items in our Consolidated Statements of Operations (in thousands):

 

   

Three months ended June 30,

   

Six months ended June 30,

 
   

2023

   

2022

   

2023

   

2022

 
                                 

Cost of revenue

  $ 41     $ 9     $ 60     $ 17  

Research and development

    45       13       65       26  

Selling

    31       5       42       11  

General and administrative

    145       65       230       135  
                                 

Total

  $ 262     $ 92     $ 397     $ 189  

 

Stock-based compensation expense in both three month periods ended June 30, 2023 and 2022 included approximately $40,000 related to restricted stock awards that directors are entitled to receive pursuant to the Director Compensation plan. Stock-based compensation expense in both six month periods ended June 30, 2023 and 2022 included approximately $80,000 related to restricted stock awards that directors are entitled to receive pursuant to the Director Compensation plan. Under this plan each of the four independent directors is entitled to an Annual Equity Retainer in the amount of $40,000, to be granted on the date of the Company’s annual meeting of shareholders.

 

For the six months ended June 30, 2023, the Company granted 254,000 stock options, vesting 25% per year over four years, with a ten-year life. The Company determined the weighted average fair value of stock options granted was $9.27 and is based upon weighted average assumptions below.

 

Stock price

  $ 14.02  

Exercise price

  $ 14.02  

Dividend yield

    0 %

Expected volatility

    72 %

Risk-free interest rate

    3.39 %

Expected life (in years)

    6.00  

 

The following table summarizes stock options awards through June 30, 2023:

 

           

Weighted

 
   

Stock Option

   

Average

 
   

Awards

   

Exercise

 
   

(in shares)

   

Price

 

Outstanding at January 1, 2023

    673,000     $ 5.70  

Granted

    244,000       14.11  

Exercised

    (17,500 )     4.19  
                 

Outstanding at March 31, 2023

    899,500       8.01  

Granted

    10,000       11.87  

Exercised

    (625 )     4.71  

Forfeited

    (3,750 )     4.01  

Outstanding at June 30, 2023

    905,125     $ 8.07  

 

The following table summarizes information about the outstanding and exercisable options at June 30, 2023 by ranges of exercise prices:

 

         

Options Outstanding

   

Options Exercisable

 
                 

Weighted

   

Weighted

                   

Weighted

         
                 

Average

   

Average

                   

Average

         

Exercise

   

Number

   

Remaining

   

Exercise

   

Intrinsic

   

Number

   

Exercise

   

Intrinsic

 

Price Range

   

Outstanding

   

Contractual

   

Price

   

Value

   

Exercisable

   

Price

   

Value

 
$4.00 - 7.00       511,125       8.3     $ 4.55     $ 1,443,308       133,000     $ 4.45     $ 388,093  
$7.01 - 10.00       20,000       4.8     $ 8.07     $ -       20,000     $ 8.07     $ -  
$10.01 - 13.00       130,000       4.5     $ 11.51     $ -       120,000     $ 10.52     $ -  
$13.01 - 16.00       244,000       9.7     $ 14.11     $ -       -       -     $ -  

 

As of June 30, 2023, there was $3.0 million of unrecognized compensation costs related to stock options expected to be recognized over a weighted average period of 3.4 years.

v3.23.2
Note 9 - Income Taxes
6 Months Ended
Jun. 30, 2023
Notes to Financial Statements  
Income Tax Disclosure [Text Block]

NOTE 9: INCOME TAXES

 

As of June 30, 2023 and December 31, 2022, the Company has provided a full valuation allowance against its net deferred tax assets. This was based on management’s assessment, including the last four years of operating losses, that it is more likely than not that the net deferred tax assets may not be realized in the future. Management continues to evaluate for potential utilization of the Company’s net deferred tax asset, which has been fully reserved for, on a quarterly basis, reviewing our economic models, including projections of future operating results.

 

v3.23.2
Note 10 - Segment Reporting
6 Months Ended
Jun. 30, 2023
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]

NOTE 10: SEGMENT REPORTING

 

The Company operates through three segments: CVD Equipment, Stainless Design Concepts (“SDC”) and CVD Materials. The CVD Equipment segment manufactures and sells chemical vapor deposition, physical vapor transport and similar equipment. The SDC segment designs and manufactures ultra-high purity gas and chemical delivery control systems. The CVD Materials segment provides material coatings for aerospace, medical, electronic and other applications and is not considered a core business of the Company. See Note 11 for the disposition of the Tantaline subsidiary and planned disposition of the MesoScribe subsidiary which comprise the CVD Materials segment. The Company evaluates performance based on several factors, of which the primary financial measure is income (loss) before taxes.

 

The Company’s corporate administration activities are reported in the “Corporate” column. These activities primarily include expenses related to certain corporate officers and support staff, expenses related to the Company’s Board of Directors, stock option expense for options and shares of restricted stock granted to corporate administration employees, certain consulting expenses, investor and shareholder relations activities, and all of the Company’s legal, auditing and professional fees.

 

Elimination entries included in the “Eliminations” column represent intersegment revenues and cost of revenues that are eliminated in consolidation. Intersegment sales by the SDC segment to the CVD Equipment segment for the three months ended June 30, 2023 and 2022 were $138,000 and $380,000, respectively and $266,000 and $425,000 for the six months ended June 30, 2023 and 2022, respectively. Intersegment sales by the CVD Equipment segment to the SDC segment for the three months and six months ended June 30, 2023 were $65,000. There were no intersegment sales by the CVD Equipment segment to the SDC segment in 2022.

 

The following table presents certain information regarding the Company’s segments as of and for the three months ended June 30, 2023 and 2022 (in thousands):

 

2023

                                               
   

CVD

Equipment

   

SDC

   

CVD

Materials

   

Eliminations

   

Corporate

   

Consolidated

 

Assets

  $ 32,139     $ 4,189     $ 483     $ (28 )   $ -     $ 36,783  
                                                 

Revenue

  $ 3,134     $ 1,795     $ 342     $ (202 )   $ -     $ 5,069  

Operating (loss) income

    (445 )     363       (224 ) *     (28 )     (898 )     (1,232 )

Pretax (loss) income

    (445 )     364       (203 ) *     (28 )     (791 )     (1,103 )

Depreciation and amortization

  $ 136     $ 12     $ 79     $ -     $ -     $ 227  

Purchase of property, plant & equipment

  $ 78     $ -     $ -     $ -     $ -     $ 78  

 

2022

                                               
   

CVD

Equipment

   

SDC

   

CVD

Materials

   

Eliminations

   

Corporate

   

Consolidated

 

Assets

  $ 23,661     $ 8,474     $ 1,913     $ 68     $ -     $ 34,116  
                                                 

Revenue

  $ 3,782     $ 1,591     $ 816     $ (380 )   $ -     $ 5,809  

Operating (loss) income

    (469 )     227       253       -       (758 )     (747 )

Pretax (loss) income

    (450 )     227       143       -       (758 )     (838 )

Depreciation and amortization

  $ 116     $ 12     $ 23     $ -     $ -     $ 151  

Purchase of property, plant & equipment

  $ 283     $ -     $ -     $ -     $ -     $ 283  

 

* Includes loss on sale of Tantaline of $0.2 million and impairment charge related to MesoScribe fixed assets of $0.1 million.

 

The following table presents certain information regarding the Company’s segments as of and for the six months ended June 30, 2023 and 2022 (in thousands):

 

2023

                                               
   

CVD

Equipment

   

SDC

   

CVD

Materials

   

Eliminations

   

Corporate

   

Consolidated

 
                                                 

Revenue

  $ 8,979     $ 4,107     $ 1,009     $ (331 )   $ -     $ 13,764  

Operating (loss) income

    (267 )     994       (143 ) *     (28 )     (1,976 )     (1,420 )

Pretax (loss) income

    (265 )     996       (95 ) *     (28 )     (1,750 )     (1,142 )

Depreciation and amortization

  $ 267     $ 24     $ 101     $ -     $ -     $ 392  

Purchase of property, plant & equipment

  $ 215     $ 10     $ -     $ -     $ -     $ 225  

 

2022

                                               
   

CVD

Equipment

   

SDC

   

CVD

Materials

   

Eliminations

   

Corporate

   

Consolidated

 
                                                 

Revenue

  $ 6,607     $ 3,006     $ 1,273     $ (425 )   $ -     $ 10,461  

Operating (loss) income

    (1,236 )     670       284       -       (1,438 )     (1,720 )

Pretax (loss) income

    (1,204 )     670       136       -       (1,438 )     (1,836 )

Depreciation and amortization

  $ 332     $ 25     $ 45     $ -     $ -     $ 402  

Purchase of property, plant & equipment

  $ 428     $ 2     $ 30     $ -     $ -     $ 460  

 

* Includes loss on sale of Tantaline of $0.2 million and impairment charge related to MesoScribe fixed assets of $0.1 million.

 

v3.23.2
Note 11 - CVD Materials - Tantaline and Mesocribe Subsidiaires
6 Months Ended
Jun. 30, 2023
Notes to Financial Statements  
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]

NOTE 11: CVD MATERIALS – TANTALINE AND MESOCRIBE SUBSIDIAIRES

 

Tantaline Subsidiary

 

On May 26, 2023, the Company sold its Tantaline subsidiary located in Nordborg, Denmark in exchange for a nominal amount at closing and an earn-out provision based on any net income that Tantaline may earn during the five-year period ending December 31, 2027. The Company recorded a loss of $0.2 million upon the sale. Any earn-out amounts will be recognized when and if any such amounts become probable of receipt.

 

The decision to sell Tantaline was based on the Company’s ongoing strategy to focus on the equipment business consisting of the CVD Equipment and SDC segments and reduce its focus on the non-core CVD Materials business.

 

Including the loss on disposition of $0.2 million, the revenues and net loss of Tantaline were $44,000 and $0.2 million respectively, for the three months ended June 30, 2023 and the revenues and net income of Tantaline were $0.5 million and $0.1 million, respectively, for the six months ended June 30, 2023. The total assets and total liabilities of the Tantaline subsidiary were $1.1 million and $0.4 million as of December 31, 2022.

 

MesoScribe Subsidiary

 

During the three months ended June 30, 2023, the Company entered into negotiations with a third party to sell certain assets and license certain propriety information of MesoScribe.

 

On August 8, 2023, the Company entered into a Purchase and License Agreement (“the Agreement”) with the third-party. Pursuant to the Agreement, the Company will sell certain proprietary assets relating to its plasma spray technology and material deposition system and grant a non-exclusive license to use certain of the Company's related intellectual property as more fully described in the Agreement, for an aggregate purchase price of $0.9 million. The purchase price is payable in several installments and contingent upon certain performance metrics and other milestones.

 

The Company will continue to fulfill remaining orders for MesoScribe products through the end of 2023 at which time it plans to cease the remaining operations of MesoScribe and dispose of any remaining equipment. During the three and six months ended June 30, 2023, the Company recorded an impairment charge of $0.1 million for certain equipment of MesoScribe based on its decision to cease the remaining operations by the end of 2023.

 

Including the impairment charge of $0.1 million, the revenues and net income of MesoScribe were $0.3 million and $0.1 million for the three months ended June 30, 2023. The revenue and net income were $0.5 million and $0.1 million respectively, for the six months ended June 30, 2023.

 

The total assets and total liabilities of the MesoScribe subsidiary were $0.4 million and $48,000, respectively, as of June 30, 2023 and $0.8 million and $0.1 million, respectively, as of December 31, 2022.

v3.23.2
Note 12 - Risks and Uncertainties
6 Months Ended
Jun. 30, 2023
Notes to Financial Statements  
Risks and Uncertainties [Text Block]

NOTE 12: RISKS AND UNCERTAINTIES

 

The Company currently operates in a challenging economic environment as the global economy continues to confront the impacts from the pandemic, geopolitical conflicts, inflationary pressures and adverse supply chain disruptions. The specific impacts on the Company have included:

 

Significant geopolitical developments across Europe and Asia (including the war in Ukraine) have and may continue to restrict the Company’s ability to procure raw materials and components such as nickel and integrated circuits, as well as impact the Company’s ability to sell its products into China, Russia and other Eastern European and Asian regions.

 

Supply chain disruptions have led to much longer lead times to acquire raw materials for production and has led to inflationary pressures in both materials and labor. These supply chain disruptions have impacted the Company’s ability to recognize revenue more timely as it delays the Company’s manufacturing processes.

 

While management has initiated actions to mitigate the potential negative impacts to its revenue and profitability, the Company is unable to predict the impact that the above uncertainties will have on its future results of operations and cash flows.

 

v3.23.2
Significant Accounting Policies (Policies)
6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Revenue from Contract with Customer [Policy Text Block]

Revenue Recognition

 

In accordance with FASB ASC 606 - Revenue from Contracts with Customers ("ASC 606"), the Company records revenue in an amount that reflects the consideration to which the Company expects to be entitled in exchange for goods or services promised to its customers. Under ASC 606, the Company follows a five-step model to: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price for the contract; (4) allocate the transaction price to the performance obligations; and (5) recognize revenue using one of the following two methods:

 

Over time

 

The Company designs, manufactures and sells custom chemical vapor deposition equipment through contractual agreements. These system sales require the Company to deliver functioning equipment that is generally completed within two to eighteen months from commencement of order acceptance. For systems sales that meet the criteria to recognize revenue over time, the Company recognizes revenue over time by using an input method based on costs incurred as it depicts the Company’s progress toward satisfaction of the performance obligation. For system sales that to not meet the criteria to recognize revenue over time based on the contract provisions, the Company recognize revenue based on point in time as discussed below.

 

Under this method, revenue arising from fixed price contracts is recognized as work is performed based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligations. Incurred costs include all direct material and labor costs and those indirect costs related to contract performance, such as supplies, tools, repairs and depreciation costs. Contract material costs are included in incurred costs when the project materials have been purchased or moved to work in process, and installed, as required by the project’s engineering design. Cost based input methods of revenue recognition require the Company to make estimates of costs to complete the projects. In making such estimates, significant judgment is required to evaluate assumptions related to the costs to complete the projects, including materials, labor and other system costs. If the estimated total costs on any contract are greater than the net contract revenues, the Company recognizes the entire estimated loss in the period the loss becomes known and can be reasonably estimated. There were no material impairment losses recognized on contract assets during the three and six months ended June 30, 2023 and 2022.

 

The timing of revenue recognition, billings and collections results in accounts receivables, unbilled receivables or contract assets and contract liabilities on our consolidated balance sheet. Under typical payment terms for our contracts accounted for over time, amounts are billed as work progresses in accordance with agreed-upon contractual terms, either at periodic intervals or upon achievement of contractual milestones.

 

Under ASC 606, payments received from customers in excess of revenue recognized to-date results in a contract liability. These contract liabilities are not considered to represent a significant financing component of the contract because we believe these cash advances and deposits are generally used to meet working capital demands which can be higher in the earlier stages of a contract. Also, advanced payments and deposits provide us with some measure of assurance that the customer will perform on its obligations under the contract.

 

Contract assets include unbilled amounts typically resulting from system sales under contracts and represents revenue recognized that exceeds the amount billed to the customer.

 

Contract liabilities include advance payments and billings in excess of revenue recognized. The Company typically receives down payments upon receipt of order and progress payments as the system is manufactured.

 

Contract assets and contract liabilities are classified as current as these contracts in progress are expected to be substantially completed within the next twelve months.

 

Point in time

 

For non-system sales of products and services, revenue is recognized at the point in time when control of the promised products or services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those products or services (the transaction price). A performance obligation is a promise in a contract to transfer a distinct product or service to a customer and is the unit of account under ASC 606, “Revenue from Contracts with Customers”.

 

For any system equipment sales where the equipment would have an alternative use or where the contract provisions of the contract preclude the use of over time revenue recognition, revenue is recognized at the point in time when control of the equipment is transferred to the customer. For the three and six months ended June 30, 2023 and 2022, all system equipment sales were recorded over time by using an input method except for one system equipment contract in 2023 where the revenue will be recognized at the point in time when the equipment is transferred to the customer.

Inventory, Policy [Policy Text Block]

Inventories

 

Inventories are valued at the lower of cost (determined on the first-in, first-out method) or net realizable value.

Standard Product Warranty, Policy [Policy Text Block]

Product Warranty

 

The Company typically provides standard warranty coverage on its systems for one year from the date of final acceptance or fifteen months from the date of shipment by providing labor and parts necessary to repair the systems during the warranty period. The Company records the estimated warranty cost when revenue is recognized on the related system. Warranty cost is included in “Cost of revenue” in the condensed consolidated statements of operations. The estimated warranty cost is based on the Company’s historical cost. The Company updates its warranty estimates based on actual costs incurred.

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Standards

 

In June 2016, the FASB issued Accounting Standard Update (“ASU”) 2016-13, Financial Instruments – Credit Losses (Topic 326), which require that financial assets measured at amortized cost be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset to present the net carrying value at the amount expected to be collected. The income statement reflects the measurement of credit losses for newly recognized financial assets, as well as the increase or decreases of expected credit losses that have taken place during the period. The measurement of expected credit losses is based upon historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. On November 15, 2019, the FASB delayed the effective date for smaller reporting companies. The amendments in this update are effective for fiscal years beginning after December 15, 2022 and interim periods within those annual periods. The adoption of the ASU 2016-3 as of January 1, 2023 did not have a material impact on the Company’s financial position.

 

The Company believes there is no additional new accounting guidance adopted, but not yet effective that is relevant to the readers of its financial statements. However, there are numerous new proposals under development which, if and when enacted, may have a significant impact on our financial reporting.

v3.23.2
Note 4 - Revenue Recognition (Tables)
6 Months Ended
Jun. 30, 2023
Notes Tables  
Disaggregation of Revenue [Table Text Block]
   

Three months ended June 30, 2023

 
                         
   

Over time

   

Point in time

   

Total

 

Energy

  $ 760     $ 38     $ 798  

Aerospace

    -       604       604  

Industrial

    1,085       915       2,000  

Research

    1,184       483       1,667  

Total

  $ 3,029     $ 2,040     $ 5,069  
   

Three months ended June 30, 2022

 
                         
   

Over time

   

Point in time

   

Total

 

Energy

  $ 2,024     $ 219     $ 2,243  

Aerospace

    -       520       520  

Industrial

    1,450       725       2,175  

Research

    299       572       871  

Total

  $ 3,773     $ 2,036     $ 5,809  
   

Six months ended June 30, 2023

 
                         
   

Over time

   

Point in time

   

Total

 

Energy

  $ 3,276     $ 52     $ 3,328  

Aerospace

    264       855       1,119  

Industrial

    4,756       1,127       5,883  

Research

    2,456       978       3,434  

Total

  $ 10,752     $ 3,012     $ 13,764  
   

Six months ended June 30, 2022

 
                         
   

Over time

   

Point in time

   

Total

 

Energy

  $ 2,923     $ 226     $ 3.149  

Aerospace

    -       1,221       1,221  

Industrial

    2,446       1,597       4,043  

Research

    1,005       1,043       2,048  

Total

  $ 6,374     $ 4,087     $ 10,461  
Schedule Of Cost And Estimated Earnings In Excess Of Billings [Table Text Block]

Costs incurred on contracts in progress

  $ 14,062  

Estimated earnings

    9,975  
      24,037  

Billings to date

    (25,525 )
      (1,488 )
Deferred revenue related to non-system contracts     (263 )
    $ (1,751 )
         

Included in accompanying condensed consolidated balance sheet as of June 30, 2023 under the following captions (in thousands):

       

Contract assets

  $ 2,951  
Contract liabilities   $ 4,702  
v3.23.2
Note 5 - Inventories, Net (Tables)
6 Months Ended
Jun. 30, 2023
Notes Tables  
Schedule of Inventory, Current [Table Text Block]

Inventories consist of:

               
   

June 30, 2023

    December 31, 2022  
                 

Raw materials

  $ 2,543     $ 2,165  

Work-in-process

    1,607       373  

Total

  $ 4,150     $ 2,538  
v3.23.2
Note 7 - Earnings Per Share (Tables)
6 Months Ended
Jun. 30, 2023
Notes Tables  
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
   

Three months ended

June 30,

   

Six months ended

June 30,

 
   

2023

   

2022

   

2023

   

2022

 
                                 

Basic weighted average common shares outstanding

    6,778,754       6,728,938       6,776,035       6,726,990  

Dilutive effect of options and unvested restricted stock

    -       -       -       -  

Diluted weighted average shares outstanding

    6,778,754       6,728,938       6,776,035       6,726,990  
v3.23.2
Note 8 - Stock-based Compensation Expense (Tables)
6 Months Ended
Jun. 30, 2023
Notes Tables  
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]
   

Three months ended June 30,

   

Six months ended June 30,

 
   

2023

   

2022

   

2023

   

2022

 
                                 

Cost of revenue

  $ 41     $ 9     $ 60     $ 17  

Research and development

    45       13       65       26  

Selling

    31       5       42       11  

General and administrative

    145       65       230       135  
                                 

Total

  $ 262     $ 92     $ 397     $ 189  
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

Stock price

  $ 14.02  

Exercise price

  $ 14.02  

Dividend yield

    0 %

Expected volatility

    72 %

Risk-free interest rate

    3.39 %

Expected life (in years)

    6.00  
Share-Based Payment Arrangement, Option, Activity [Table Text Block]
           

Weighted

 
   

Stock Option

   

Average

 
   

Awards

   

Exercise

 
   

(in shares)

   

Price

 

Outstanding at January 1, 2023

    673,000     $ 5.70  

Granted

    244,000       14.11  

Exercised

    (17,500 )     4.19  
                 

Outstanding at March 31, 2023

    899,500       8.01  

Granted

    10,000       11.87  

Exercised

    (625 )     4.71  

Forfeited

    (3,750 )     4.01  

Outstanding at June 30, 2023

    905,125     $ 8.07  
Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]
         

Options Outstanding

   

Options Exercisable

 
                 

Weighted

   

Weighted

                   

Weighted

         
                 

Average

   

Average

                   

Average

         

Exercise

   

Number

   

Remaining

   

Exercise

   

Intrinsic

   

Number

   

Exercise

   

Intrinsic

 

Price Range

   

Outstanding

   

Contractual

   

Price

   

Value

   

Exercisable

   

Price

   

Value

 
$4.00 - 7.00       511,125       8.3     $ 4.55     $ 1,443,308       133,000     $ 4.45     $ 388,093  
$7.01 - 10.00       20,000       4.8     $ 8.07     $ -       20,000     $ 8.07     $ -  
$10.01 - 13.00       130,000       4.5     $ 11.51     $ -       120,000     $ 10.52     $ -  
$13.01 - 16.00       244,000       9.7     $ 14.11     $ -       -       -     $ -  
v3.23.2
Note 10 - Segment Reporting (Tables)
6 Months Ended
Jun. 30, 2023
Notes Tables  
Schedule of Segment Reporting Information, by Segment [Table Text Block]

2023

                                               
   

CVD

Equipment

   

SDC

   

CVD

Materials

   

Eliminations

   

Corporate

   

Consolidated

 

Assets

  $ 32,139     $ 4,189     $ 483     $ (28 )   $ -     $ 36,783  
                                                 

Revenue

  $ 3,134     $ 1,795     $ 342     $ (202 )   $ -     $ 5,069  

Operating (loss) income

    (445 )     363       (224 ) *     (28 )     (898 )     (1,232 )

Pretax (loss) income

    (445 )     364       (203 ) *     (28 )     (791 )     (1,103 )

Depreciation and amortization

  $ 136     $ 12     $ 79     $ -     $ -     $ 227  

Purchase of property, plant & equipment

  $ 78     $ -     $ -     $ -     $ -     $ 78  

2022

                                               
   

CVD

Equipment

   

SDC

   

CVD

Materials

   

Eliminations

   

Corporate

   

Consolidated

 

Assets

  $ 23,661     $ 8,474     $ 1,913     $ 68     $ -     $ 34,116  
                                                 

Revenue

  $ 3,782     $ 1,591     $ 816     $ (380 )   $ -     $ 5,809  

Operating (loss) income

    (469 )     227       253       -       (758 )     (747 )

Pretax (loss) income

    (450 )     227       143       -       (758 )     (838 )

Depreciation and amortization

  $ 116     $ 12     $ 23     $ -     $ -     $ 151  

Purchase of property, plant & equipment

  $ 283     $ -     $ -     $ -     $ -     $ 283  

2023

                                               
   

CVD

Equipment

   

SDC

   

CVD

Materials

   

Eliminations

   

Corporate

   

Consolidated

 
                                                 

Revenue

  $ 8,979     $ 4,107     $ 1,009     $ (331 )   $ -     $ 13,764  

Operating (loss) income

    (267 )     994       (143 ) *     (28 )     (1,976 )     (1,420 )

Pretax (loss) income

    (265 )     996       (95 ) *     (28 )     (1,750 )     (1,142 )

Depreciation and amortization

  $ 267     $ 24     $ 101     $ -     $ -     $ 392  

Purchase of property, plant & equipment

  $ 215     $ 10     $ -     $ -     $ -     $ 225  

2022

                                               
   

CVD

Equipment

   

SDC

   

CVD

Materials

   

Eliminations

   

Corporate

   

Consolidated

 
                                                 

Revenue

  $ 6,607     $ 3,006     $ 1,273     $ (425 )   $ -     $ 10,461  

Operating (loss) income

    (1,236 )     670       284       -       (1,438 )     (1,720 )

Pretax (loss) income

    (1,204 )     670       136       -       (1,438 )     (1,836 )

Depreciation and amortization

  $ 332     $ 25     $ 45     $ -     $ -     $ 402  

Purchase of property, plant & equipment

  $ 428     $ 2     $ 30     $ -     $ -     $ 460  
v3.23.2
Note 1 - Basis of Presentation (Details Textual) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Cash and Cash Equivalents, at Carrying Value $ 13,033 $ 14,365
v3.23.2
Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Capitalized Contract Cost, Impairment Loss $ 0 $ 0 $ 0 $ 0
Standard Product Warranty, Period From Final Acceptance     1 year  
Standard Product Warranty, Period From Date of Shipment     15 months  
v3.23.2
Note 3 - Concentration of Credit Risk (Details Textual) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Cash and Cash Equivalents, at Carrying Value $ 13,033,000   $ 13,033,000   $ 14,365,000
Cash Equivalents, at Carrying Value 10,000,000.0   10,000,000.0   11,700,000
Cash, Uninsured Amount 2,600,000   2,600,000   1,500,000
Accounts Receivable, Allowance for Credit Loss, Current $ 36,000   $ 36,000   $ 36,000
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Two Customers [Member]          
Concentration Risk, Percentage     46.00%   66.00%
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Customer A [Member]          
Concentration Risk, Percentage 16.00% 24.00% 21.00% 16.00%  
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Customer B [Member]          
Concentration Risk, Percentage 16.00% 15.00% 16.00% 12.00%  
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Customer C [Member]          
Concentration Risk, Percentage 11.00%        
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Customer D [Member]          
Concentration Risk, Percentage 10.00%        
DENMARK          
Cash, Uninsured Amount         $ 500,000
v3.23.2
Note 4 - Revenue Recognition 1 (Details Textual) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Contract with Customer, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price and Input Costs $ 4,500      
Contract with Customer, Liability 4,702   $ 4,000 $ 1,700
Contract with Customer, Liability, Revenue Recognized $ 2,600 $ 1,600    
v3.23.2
Note 4 - Revenue Recognition 2 (Details Textual) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-07-01
$ in Millions
Jun. 30, 2023
USD ($)
Revenue, Remaining Performance Obligation, Amount $ 12.1
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period 12 months
v3.23.2
Note 4 - Revenue Recognition - Disaggregation of Revenue (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenue $ 5,069,000 $ 5,809,000 $ 13,764,000 $ 10,461,000
Energy, Storage and Transmission [Member]        
Revenue 798,000 2,243,000 3,328,000 3,149
Aerospace [Member]        
Revenue 604,000 520,000 1,119,000 1,221,000
Industrial [Member]        
Revenue 2,000,000 2,175,000 5,883,000 4,043,000
Research [Member]        
Revenue 1,667,000 871,000 3,434,000 2,048,000
Transferred over Time [Member]        
Revenue 3,029,000 3,773,000 10,752,000 6,374,000
Transferred over Time [Member] | Energy, Storage and Transmission [Member]        
Revenue 760,000 2,024,000 3,276,000 2,923,000
Transferred over Time [Member] | Aerospace [Member]        
Revenue 0 0 264,000 0
Transferred over Time [Member] | Industrial [Member]        
Revenue 1,085,000 1,450,000 4,756,000 2,446,000
Transferred over Time [Member] | Research [Member]        
Revenue 1,184,000 299,000 2,456,000 1,005,000
Transferred at Point in Time [Member]        
Revenue 2,040,000 2,036,000 3,012,000 4,087,000
Transferred at Point in Time [Member] | Energy, Storage and Transmission [Member]        
Revenue 38,000 219,000 52,000 226,000
Transferred at Point in Time [Member] | Aerospace [Member]        
Revenue 604,000 520,000 855,000 1,221,000
Transferred at Point in Time [Member] | Industrial [Member]        
Revenue 915,000 725,000 1,127,000 1,597,000
Transferred at Point in Time [Member] | Research [Member]        
Revenue $ 483,000 $ 572,000 $ 978,000 $ 1,043,000
v3.23.2
Note 4 - Revenue Recognition - Costs, Estimated Earnings, and Billings on Uncompleted Contracts (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Dec. 31, 2021
Costs incurred on contracts in progress $ 14,062    
Estimated earnings 9,975    
Costs and Estimated Earnings on Uncompleted Contracts 24,037    
Billings to date (25,525)    
Net Cost in Excess of Billings (1,488)    
Deferred revenue related to non-system contracts (263)    
Contract Liability In Excess of Contract Assets (1,751)    
Contract assets 2,951    
Contract liabilities $ 4,702 $ 4,000 $ 1,700
v3.23.2
Note 5 - Inventories, Net - Components of Inventories (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Raw materials $ 2,543 $ 2,165
Work-in-process 1,607 373
Total $ 4,150 $ 2,538
v3.23.2
Note 6 - Long-term Debt (Details Textual) - Loan Agreement to Fund Machinery Acquisition [Member]
1 Months Ended
Sep. 30, 2022
USD ($)
Debt Instrument, Face Amount $ 432,000
Debt Instrument, Number of Payments 60
Debt Instrument, Periodic Payment $ 8,352
Debt Instrument, Interest Rate, Stated Percentage 6.00%
v3.23.2
Note 7 - Earnings Per Share (Details Textual) - shares
Jun. 30, 2023
Mar. 31, 2023
Dec. 31, 2022
Jun. 30, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number 905,125 899,500 673,000 599,500
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number 273,000     297,500
v3.23.2
Note 7 - Earnings Per Share - Calculation of Basic and Diluted Weighted Average Common Shares (Details) - shares
shares in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Basic weighted average common shares outstanding (in shares) 6,778,754 6,728,938 6,776,035 6,726,990
Dilutive effect of options and unvested restricted stock (in shares) 0 0 0 0
Diluted weighted average shares outstanding (in shares) 6,778,754 6,728,938 6,776,035 6,726,990
v3.23.2
Note 8 - Stock-based Compensation Expense (Details Textual) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Share-Based Payment Arrangement, Expense $ 262,000   $ 92,000 $ 397,000 $ 189,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross 10,000 244,000   254,000  
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value       $ 9.27  
Share-Based Payment Arrangement, Option [Member]          
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period       4 years  
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period       10 years  
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $ 3,000,000.0     $ 3,000,000.0  
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition       3 years 4 months 24 days  
Share-Based Payment Arrangement, Option [Member] | Share-Based Payment Arrangement, Tranche One [Member]          
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage       25.00%  
Director [Member]          
Share-based Payment Arrangement, Annual Equity Reatiner 40,000     $ 40,000  
Director [Member] | Restricted Stock [Member]          
Share-Based Payment Arrangement, Expense $ 40,000   $ 40,000 $ 80,000 $ 80,000
v3.23.2
Note 8 - Stock-based Compensation Expense - Compensation Expense (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Stock-based compensation $ 262 $ 92 $ 397 $ 189
Cost of Revenue [Member]        
Stock-based compensation 41 9 60 17
Research and Development Expense [Member]        
Stock-based compensation 45 13 65 26
Selling and Shipping [Member]        
Stock-based compensation 31 5 42 11
General and Administrative Expense [Member]        
Stock-based compensation $ 145 $ 65 $ 230 $ 135
v3.23.2
Note 8 - Stock-based Compensation Expense - Assumptions (Details)
6 Months Ended
Jun. 30, 2023
$ / shares
Stock price (in dollars per share) $ 14.02
Exercise price (in dollars per share) $ 14.02
Dividend yield 0.00%
Expected volatility 72.00%
Risk-free interest rate 3.39%
Expected life (in years) (Year) 6 years
v3.23.2
Note 8 - Stock-based Compensation Expense - Stock Option Plan (Details) - $ / shares
3 Months Ended 6 Months Ended
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2023
Outstanding at January 1, 2023 (in shares) 899,500 673,000 673,000
Outstanding, weighted average exercise price (in dollars per share) $ 8.01 $ 5.70 $ 5.70
Granted (in shares) 10,000 244,000 254,000
Granted, weighted average exercise price (in dollars per share) $ 11.87 $ 14.11  
Exercised (in shares) (625) (17,500)  
Exercised, weighted average exercise price (in dollars per share) $ 4.71 $ 4.19  
Forfeited (in shares) (3,750)    
Forfeited, weighted average exercise price (in dollars per share) $ 4.01    
Outstanding at March 31, 2023 (in shares) 905,125 899,500 905,125
Outstanding, weighted average exercise price (in dollars per share) $ 8.07 $ 8.01 $ 8.07
v3.23.2
Note 8 - Stock-based Compensation Expense - Outstanding and Exercisable Options (Details)
6 Months Ended
Jun. 30, 2023
USD ($)
$ / shares
shares
Exercise price range, lower limit (in dollars per share) $ 13.01
Exercise price range, upper limit (in dollars per share) $ 16.00
Number of options outstanding (in shares) | shares 244,000
Number of options outstanding, weighted average remaining contractual term (Year) 9 years 8 months 12 days
Number of options outstanding, weighted average exercise price (in dollars per share) $ 14.11
Number of options outstanding, intrinsic value | $ $ 0
Number of options exercisable (in shares) | shares 0
Number of options exercisable, weighted average exercise price (in dollars per share) $ 0
Number of options exercisable, intrinsic value | $ $ 0
Exercise Price Range 1 [Member]  
Exercise price range, lower limit (in dollars per share) $ 4.00
Exercise price range, upper limit (in dollars per share) $ 7.00
Number of options outstanding (in shares) | shares 511,125
Number of options outstanding, weighted average remaining contractual term (Year) 8 years 3 months 18 days
Number of options outstanding, weighted average exercise price (in dollars per share) $ 4.55
Number of options outstanding, intrinsic value | $ $ 1,443,308
Number of options exercisable (in shares) | shares 133,000
Number of options exercisable, weighted average exercise price (in dollars per share) $ 4.45
Number of options exercisable, intrinsic value | $ $ 388,093
Exercise Price Range 2 [Member]  
Exercise price range, lower limit (in dollars per share) $ 7.01
Exercise price range, upper limit (in dollars per share) $ 10.00
Number of options outstanding (in shares) | shares 20,000
Number of options outstanding, weighted average remaining contractual term (Year) 4 years 9 months 18 days
Number of options outstanding, weighted average exercise price (in dollars per share) $ 8.07
Number of options outstanding, intrinsic value | $ $ 0
Number of options exercisable (in shares) | shares 20,000
Number of options exercisable, weighted average exercise price (in dollars per share) $ 8.07
Number of options exercisable, intrinsic value | $ $ 0
Exercise Price Range 3 [Member]  
Exercise price range, lower limit (in dollars per share) $ 10.01
Exercise price range, upper limit (in dollars per share) $ 13.00
Number of options outstanding (in shares) | shares 130,000
Number of options outstanding, weighted average remaining contractual term (Year) 4 years 6 months
Number of options outstanding, weighted average exercise price (in dollars per share) $ 11.51
Number of options outstanding, intrinsic value | $ $ 0
Number of options exercisable (in shares) | shares 120,000
Number of options exercisable, weighted average exercise price (in dollars per share) $ 10.52
Number of options exercisable, intrinsic value | $ $ 0
v3.23.2
Note 10 - Segment Reporting (Details Textual)
3 Months Ended 6 Months Ended
May 26, 2023
USD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2022
USD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2022
USD ($)
Number of Operating Segments       3  
Revenue from Contract with Customer, Including Assessed Tax   $ 5,069,000 $ 5,809,000 $ 13,764,000 $ 10,461,000
Loss on disposition of Tantaline   162,000 0 162,000 0
Asset Impairment Charges   111,000 0 111,000 0
MesoScribe Technologies, Inc [Member]          
Revenue from Contract with Customer, Including Assessed Tax   300,000   500,000  
Asset Impairment Charges   100,000   100,000  
Tantaline A/S of Nordborg [Member]          
Loss on disposition of Tantaline $ 200,000 200,000   200,000  
Intersegment Eliminations [Member]          
Revenue from Contract with Customer, Including Assessed Tax   (202,000) (380,000) (331,000) (425,000)
Intersegment Eliminations [Member] | SDC [Member]          
Revenue from Contract with Customer, Including Assessed Tax   138,000 $ 380,000 266,000 425,000
Intersegment Eliminations [Member] | CVD [Member]          
Revenue from Contract with Customer, Including Assessed Tax   $ 65,000   $ 65,000 $ 0
v3.23.2
Note 10 - Segment Reporting - Segment Information (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Assets $ 36,783,000 $ 34,116,000 $ 36,783,000 $ 34,116,000 $ 37,912,000
Revenue 5,069,000 5,809,000 13,764,000 10,461,000  
Operating (loss) income (1,232,000) (747,000) (1,420,000) [1] (1,720,000)  
Pretax (loss) income (1,103,000) (838,000) (1,142,000) [1] (1,836,000)  
Depreciation and amortization 227,000 151,000 392,000 402,000  
Purchase of property, plant & equipment 78,000 283,000 225,000 460,000  
Intersegment Eliminations [Member]          
Assets (28,000) 68,000 (28,000) 68,000  
Revenue (202,000) (380,000) (331,000) (425,000)  
Operating (loss) income (28,000) 0 (28,000) [1] 0  
Pretax (loss) income (28,000) 0 (28,000) [1] 0  
Depreciation and amortization 0 0 0 0  
Purchase of property, plant & equipment 0 0 0 0  
Corporate, Non-Segment [Member]          
Assets 0 0 0 0  
Revenue 0 0 0 0  
Operating (loss) income (898,000) (758,000) (1,976,000) [1] (1,438,000)  
Pretax (loss) income (791,000) (758,000) (1,750,000) [1] (1,438,000)  
Depreciation and amortization 0 0 0 0  
Purchase of property, plant & equipment 0 0 0 0  
CVD [Member] | Operating Segments [Member]          
Assets 32,139,000 23,661,000 32,139,000 23,661,000  
Revenue 3,134,000 3,782,000 8,979,000 6,607,000  
Operating (loss) income (445,000) (469,000) (267,000) [1] (1,236,000)  
Pretax (loss) income (445,000) (450,000) (265,000) [1] (1,204,000)  
Depreciation and amortization 136,000 116,000 267,000 332,000  
Purchase of property, plant & equipment 78,000 283,000 215,000 428,000  
CVD [Member] | Intersegment Eliminations [Member]          
Revenue 65,000   65,000 0  
SDC [Member] | Operating Segments [Member]          
Assets 4,189,000 8,474,000 4,189,000 8,474,000  
Revenue 1,795,000 1,591,000 4,107,000 3,006,000  
Operating (loss) income 363,000 227,000 994,000 [1] 670,000  
Pretax (loss) income 364,000 227,000 996,000 [1] 670,000  
Depreciation and amortization 12,000 12,000 24,000 25,000  
Purchase of property, plant & equipment 0 0 10,000 2,000  
SDC [Member] | Intersegment Eliminations [Member]          
Revenue 138,000 380,000 266,000 425,000  
Materials [Member] | Operating Segments [Member]          
Assets 483,000 1,913,000 483,000 1,913,000  
Revenue 342,000 816,000 1,009,000 1,273,000  
Operating (loss) income (224,000) [2] 253,000 (143,000) [1] 284,000  
Pretax (loss) income (203,000) [2] 143,000 (95,000) [1] 136,000  
Depreciation and amortization 79,000 23,000 101,000 45,000  
Purchase of property, plant & equipment $ 0 $ 0 $ 0 $ 30,000  
[1] Includes loss on sale of Tantaline of $0.2 million and impairment charge related to MesoScribe fixed assets of $0.1 million.
[2] Includes loss on sale of Tantaline of $0.2 million and impairment charge related to MesoScribe fixed assets of $0.1 million.
v3.23.2
Note 11 - CVD Materials - Tantaline and Mesocribe Subsidiaires (Details Textual) - USD ($)
3 Months Ended 6 Months Ended
May 26, 2023
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Aug. 08, 2023
Dec. 31, 2022
Loss on disposition of Tantaline   $ 162,000 $ 0 $ 162,000 $ 0    
Asset Impairment Charges   111,000 0 111,000 0    
Revenue from Contract with Customer, Including Assessed Tax   5,069,000 5,809,000 13,764,000 10,461,000    
Net Income (Loss) Attributable to Parent   (1,113,000) (839,000) (1,153,000) (1,837,000)    
Assets   36,783,000 $ 34,116,000 36,783,000 $ 34,116,000   $ 37,912,000
Liabilities   8,064,000   8,064,000     8,513,000
MesoScribe Technologies, Inc [Member]              
Asset Impairment Charges   100,000   100,000      
Revenue from Contract with Customer, Including Assessed Tax   300,000   500,000      
Net Income (Loss) Attributable to Parent   100,000   100,000      
Assets   400,000   400,000     800,000
Liabilities   48,000   48,000     100,000
MesoScribe Technologies, Inc [Member] | Subsequent Event [Member]              
Sale of Proprietary Assets and License Certain Propriety Information, Aggregate Purchase Price           $ 900,000  
Tantaline A/S of Nordborg [Member]              
Loss on disposition of Tantaline $ 200,000 200,000   200,000      
Disposal Group, Including Discontinued Operation, Revenue   44,000   500,000      
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent   200,000   (100,000)      
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent   $ (200,000)   $ 100,000      
Disposal Group, Including Discontinued Operation, Assets             1,100,000
Disposal Group, Including Discontinued Operation, Liabilities             $ 400,000

CVD Equipment (NASDAQ:CVV)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more CVD Equipment Charts.
CVD Equipment (NASDAQ:CVV)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more CVD Equipment Charts.